

Address and Telephone

University of Florida
Department of Pharmacotherapy and Translational Research
College of Pharmacy
1345 Center Drive
MSB Room PG-27
PO Box 100486
Gainesville, FL 32610-0486 USA
Email: gong@cop.ufl.edu
Tel: (352) 273-6297
Fax: (352) 273-6121

EDUCATION/TRAINING

2018 – 2019 Graduate Certificate in Biomedical Informatics, University of Florida
2004 – 2005 Postdoctoral Fellow in Pharmacogenomics, University of Florida
1999 – 2004 Ph.D in Pharmaceutics, University of Florida
2001 – 2003 Master of Statistics, University of Florida
1996 – 1999 Master of Science in Pharmaceutics, West China University of Medical Sciences
(later merged with Sichuan University), Chengdu, Sichuan, CHINA

ACADEMIC POSITIONS/EMPLOYMENT

2016 – Present	Associate Professor, University of Florida, College of Pharmacy, Department of Pharmacotherapy and Translational Research, Gainesville, FL
2011 – 2016	Research Associate Professor, University of Florida, College of Pharmacy, Department of Pharmacotherapy and Translational Research, Gainesville, FL
2005 – 2011	Research Assistant Professor, University of Florida, College of Pharmacy, Department of Pharmacotherapy and Translational Research, Gainesville, FL
2004 – 2005	Postdoctoral Fellow, University of Florida College of Pharmacy, Cardiovascular Pharmacogenomics, Department of Pharmacy Practice. Mentor: Julie A. Johnson, Pharm.D.
1999 – 2004	Teaching Assistant, Department of Pharmaceutics, University of Florida, Gainesville, FL.

1996 – 1999 Teaching Assistant, School of Pharmacy, West China University of Medical Sciences, Chengdu, Sichuan, P.R.CHINA

HONORS AND AWARDS

Award for Outstanding Academic Achievement by an International Student, 2000
Travel Award, American Association of Pharmaceutical Scientist, 2003
Oral finalist, Research Showcase, University of Florida College of Pharmacy, 2004
Scholar-in-training Travel Award, Pharmacogenetics Research network, 2005
Best Poster, American Society of Clinical Pharmacology and Therapeutics, 2005
Presidential Trainee Award Winner, American Society for Clinical Pharmacology and Therapeutics, 2006
Open Access Award, University of Florida, 2012
NIGMS Bursary Award, 2013
Faculty Enhancement PROSPER Award, University of Florida College of Pharmacy, 2015
New England Journal of Medicine SPRINT Data Analysis Challenge Finalist, 2017

RESEARCH

ACTIVE RESEARCH SUPPORT

CTSI COVID-19 Rapid-Response Research (PI: Gong) June 2020 - Dec 2020
NIH/NCATS

‘Genomics and Pharmacogenomics of susceptibility and severity of COVID-19 in the UK Biobank.’

The objective of this project is to identify genetic, pharmacogenetic and nongenetic risk factors for susceptibility and severity of COVID-19 in UKB participants.

Role: Principal Investigator

PROSPER Seed Award (PI: Gong) July 2019 - Sep 2020
UF College of Pharmacy

‘Global Metabolomic Profiling of Proteasome Inhibitor Carfilzomib-Related Heart Failure in Multiple Myeloma Patients.’

The goal of this project is to identify baseline metabolomic biomarkers for carfilzomib-related heart failure in multiple myeloma patients using an untargeted metabolomics approach.

Role: Principal Investigator

CTSI/UFII Big Data in Health Pilot Award (PI: Gong) June 2019 - May 2020
NIH/NCATS

‘Toward prevention of cardiotoxicity in cancer: a multimodal approach leveraging genomics, images and clinical data.’

The goal of this project is to explore a novel approach to identify patients predisposed to cancer therapy induced cardiotoxicity through interrogation of pharmacogenomics, medical images and clinical factors linked in the electronic health records in the UK Biobank data.

Role: Principal Investigator

CTSI Non-Patient Oriented Pilot Award (PI: Gong) April 2018 - Oct 2019

NIH/NCATS

‘Cancer therapy induced cardiotoxicity in the OneFlorida Consortium’

The goal of this project is to develop a computable phenotype for cancer drugs induced cardiotoxicity in the electronic health records in order to evaluate these clinically significant adverse events in the real-world clinical settings of OneFlorida Clinical Research Consortium.

Role: Principal Investigator

R01HD093612 (PI: Markowitz)

July 2018 – June 2023

NIH/NICHHD

“Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD”

The objective of this proposal is to further identify and characterize genetic variants that affect CES1 expression and activity and reveal key associations between CES1 genotypes and the PK and pharmacodynamics (PD) of MPH in ADHD patients.

Role: Co-Investigator

R01HD071779 (PI: Kwara)

July 2018 – June 2023

NIH/NICHHD

“Pharmacokinetics of Anti-tuberculosis and Antiretroviral Drugs in Children”

The objective of this proposal is to determine the PK of the first-line anti-TB and anti-HIV drugs, as well as characterize the factors associated with variable PK and drug-drug interactions in children in Ghana, West Africa.

Role: Co-Investigator

U01HG007269 (PI: Johnson)

Sep 2018 – June 2023

NIH/NHGRI

“Sparking Advancements in Genomic Medicine”

The objective of this proposal is to test the hypothesis that CYP2D6 genotype-guided pain management leads to improved patient reported outcomes for pain control and is cost-effective in a real-world setting.

Role: Co-Investigator

R24GM119977 (PI: Terada)

July 2016 – June 2019

NIH/NIGMS

“A Stem Cell Tactic to Promote Personalized Medicine”

The goal of this project is to establish a Pharmacogenomics induced pluripotent stem cells (iPSCs) Library and Service (PiLS) resource.

Role: Co-Investigator

R01 DE019456 (PI: Shaddox)

June 2014 – May 2019

NIH/NIDCR

“Mechanisms and Treatment Response of Aggressive Periodontitis in Children”

The purpose of this study is to investigate genetic, epigenetic and immunological pathways responsible for the LPS hyper-inflammatory response seen in children with aggressive periodontitis.

Role: Co-Investigator

PENDING RESEARCH SUPPORT

R01DE030538 (PI: Gong)
NIH/NIDCR

April 2021 – March 2026

‘Toward a Precision Medicine Approach to Medication-related Osteonecrosis of the Jaw.’
Role: Principal Investigator

R01HL151659 (PI: Gong)
NIH/NHLBI/NCI

Sep 2020 – August 2024

‘A multi-omics evaluation of carfilzomib-related cardiotoxicity in multiple myeloma patients.’
Role: Principal Investigator

COMPLETED RESEARCH SUPPORT

U01FD005235 (PI: Cavallari)
NIH/FDA

Sep 2014 – August 2018

“Pharmacokinetic and Pharmacodynamic (PK-PD) Studies of Cardiovascular Drugs”
The goal of this project is to provide pharmacokinetic and pharmacodynamic data to help the FDA better understand which factors should be considered in bioequivalence studies of metoprolol ER products.
Role: Co-Investigator

U01HG007269 (PI: Johnson)
NIH/NHGRI

May 2013 – April 2018

“Genomic Medicine Implementation: The Personalized Medicine Program”
This grant supports genomic medicine implementation. Its aims include an expansion of the UF Health Personalized Medicine Program, outreach to initiate genomic medicine implementation at two cardiology practice groups within Orlando Health, and at community hospitals that are part of the Florida State University Medical School network and to develop innovative educational programming for health sciences students, practitioners and patients.
Role: Co-investigator

U01 GM074492 (PIs: Johnson & Cooper-DeHoff)
NIH/NIGMS

August 2010 - July 2015

“Pharmacogenomic Evaluation of Antihypertensive Response (PEAR)”
This study aims to advance hypertension pharmacogenomics, focusing defining replicated genetic determinants of the antihypertensive and adverse metabolic effects of thiazide diuretics and beta-blockers, along with the genetic determinants of long term cardiovascular outcomes and new-onset diabetes with these same drugs. We also seek to define the mechanistic underpinnings of the genetic associations
Role: Co-investigator

U01 GM092655 (PI: Sadee)
NIH/NIGMS

August 2010 - July 2015

“Expression Genetics in Drug Therapy”

The purpose of this program is to identify the role of differential expression genetics as a source of genetic variability in drug response. Our role in the project is to test genetic associations of drug response in antihypertensive drug response datasets at the University of Florida.

Role: Co-investigator

R-238 (PI: Gong)

August 2014 – August 2015

Micromedic Technologies

“Genetic Risk Factors Associated with Bisphosphonate-Associated Osteonecrosis of the Jaw (BONJ) Occurrence”

This purpose of this grant is to identify genetic polymorphisms contributing to osteonecrosis of the Jaw in patients taking bisphosphonates using Whole Exome sequencing technology.

Role: Principal investigator

Lockheed Martin (PI: Conlon)

August 2014-August 2015

“Evaluation of quantum computation augmented machine learning algorithm for identifying pharmacogenomics biomarkers during adaptive clinical trials.”

Role: Co-investigator

R01 NS073346 (PI: Johnson)

March 2011 – Feb 2014

NIH/NINDS

“Secondary Prevention of Subcortical Stroke Prevention Genetic Substudy”

Role: co-investigator

NIH/NHLBI RS&G service (PI: Gong)

Title: “Confirming Pharmacogenomics Signals for Antihypertensive Response in INVEST-GENES”

Role: Principal Investigator

K23HL081245 (PI: Blake)

August 2006 – July 2012

NIH/NHLBI

“Pharmacogenetic Studies of β_2 agonists in Asthma”

Role: co-mentor

RC2 GM092729-01 (PI: Kaddurah-Daouk)

October 2010 - September 2012

NIH/NIGMS

“Metabolomics Network for Drug Response Phenotype”

This grant is to support metabolomics analyses within the PEAR study population

Role: Co-investigator

R01 HL074730 (PI: Johnson)

September 2009 - August 2010

NIH/NHLBI

“Hypertension pharmacogenetics”

The aims of this study are to: 1) Determine SNPs in five genes relevant to calcium regulation and the calcium channel blocker response; 2) Determine *in vitro* functional consequences of discovered polymorphisms; 3) Determine association between sequence variability in relevant

genes and antihypertensive response to verapamil; 4) Determine associations between genotype and outcomes (death, myocardial infarction, stroke) for patients taking atenolol, verapamil, trandolapril and hydrochlorothiazide; 5) Determine the role of assessing population stratification and ancestral proportions using genetic markers in pharmacogenetic studies.
Role: Co-investigator

**U01 GM074492 (PI: Johnson)
NIH/NIGMS**

September 2005 - August 2010

“Pharmacogenomic Evaluation of Antihypertensive Response (PEAR)”

The aims of this study are to: identify genetic predictors of the antihypertensive and adverse metabolic responses to a β -blocker (atenolol) and a thiazide diuretics (HCTZ), first by testing 7 SNPs in each of 70 candidate genes for genetic association with: antihypertensive responses to monotherapy (Aim 1a), addition of a second drug to monotherapy (Aim 1b), and combination therapy (Aim 1c); and adverse metabolic responses to mono and combination therapy (Aim 1d). Aim 2 seeks to identify genetic associations with these same responses through testing of 20,000 putative functional SNPs that span the human genome.

Role: co-investigator

R-238 (PI: Katz)

September 2008 - September 2010

Micromedic Technologies

“Pharmacogenetics, pharmacokinetics and bone markers

Pharmacogenomics study of Bisphosphonate-Associated Osteonecrosis of the Jaw (BONJ) “

Role: Co-investigator

BOOK CHAPTERS

Sullivan S, **Gong Y**, Hughes JA. Cationic liposomes in gene delivery. *Liposomes, a practical approach, second edition*. Oxford University Press; 2002:289-301.

Gong Y, McDonough CW, Padmanabhan S, Johnson JA. Hypertension Pharmacogenomics. *Handbook of Pharmacogenomics and Stratified Medicine*. Academic Press Inc; 2014: 747-778.

ORIGINAL PUBLICATIONS (IN REVERSE CHRONOLOGICAL ORDER):

<http://www.ncbi.nlm.nih.gov/sites/myncbi/yan.gong.1/bibliography/40498735/public/?sort=date&direction=descending>

1. Thomas CD, Mosley SA, El-Rouby N, Kim S, Lingineni K, Langae T, **Gong Y**, Schmidt SO, Schmidt S, Wang D, Frye RF, Johnson JA, Cavallari LH. Examination of Metoprolol Pharmacokinetics and Pharmacodynamics across CYP2D6 genotype-derived activity scores. *Submitted*, 2020.
2. Mehanna M, Chen YE, **Gong Y**, Handberg E, Roth B, De Leon J, Smith S, Harrel JG, Cooper-DeHoff RM. OPTImizing Precision of Hypertension Care to Maximize Blood Pressure Control (OPTI-BP): A Pilot Study Utilizing a Smartphone App to incorporate Plasma Renin Activity Testing. *Journal of Clinical Hypertension*, *submitted*, 2020.

3. Campbell D, Aman A, Iniesta R, Menni C, **Gong Y**, Singh S, Boerwinkle E, Turner ST, Chapman AB, Gums JG, Johnson JA, Burgess KE, Barrett MP, Lewis C, Cooper-DeHoff RM, Chowienczyk P, Padmanabhan S. Pharmacometabolomics of Anti-Hypertensive Drug Response. *Submitted*, 2020.
4. Shah CP, Fradley MG, Waheed N, Cooper-DeHoff RM, Hongzhi Xu, Jiang B, DeRemer DL, Yuan L, Langaee T, Pepine CJ, Hogan W, Wu Y, Moreb JS, **Gong Y**. Cardiotoxicity Related to proteasome inhibitors in Real-World Practice: Results from the OneFlorida Clinical Research Consortium. *Submitted*, 2020.
5. Yu Z, Yang X, Chen Y, Fang R, Hogan WR, **Gong Y**, Wu Y. Identify Cancer Patients at Risk for Heart Failure using Electronic Health Record and Genetic Data. submitted to AMIA 2020.
6. Yang G, Collins J, Rafiee R, Singh S, Langaee L., McDonough CW, Holliday LS, Wang DX, Lamba J, Kim YS, Pelliccioni GA, Vaszilko M, Kosa JP, Balla B, Lakatos PA, Katz J, Moreb JS, **Gong Y**. *SIRT1* Gene SNP rs932658 is Associated with Bisphosphonates-related Osteonecrosis of the Jaw. *J Bone Miner Res. in press*, 2020.
7. Waheed N, Fradley MG, DeRemer D, Mahmoud A, Shah CP, Langaee TY, Lipori GP, March K, Pepine CJ, Cooper-DeHoff RM, Wu Y, **Gong Y**. Cardiotoxicity Associated with Immune Checkpoint Inhibitors: A retrospective analysis of patients at an academic tertiary care center. *Cardio-Oncology, in press*, 2020.
8. Lee CR, Thomas CD, Beitelshes AL, Tuteja S, Empey PE, Lee JC, Limdi NA, Duarte JD, Skaar TC, Chen Y, Cook KJ, Coons JC, Dillon C, Franchi F, **Gong Y**, Kreutz RP, McDonough CW, Stevenson JM, Weck KE, Angiolillo DJ, Johnson JA, Stouffer GA, Cavallari JH. Impact of the CYP2C19*17 allele on outcomes in patients receiving genotype-guided antiplatelet therapy after percutaneous coronary intervention. *Clin Pharmacol Ther., in press*, 2020.
9. Arwood MJ, McDonough CW, Cavallari LH, Elsey AR, Frye RF, **Gong Y**, Langaee T, Johnson JA, Wiisanen K. Evaluating an interactive teaching approach with personal genotyping to provide pharmacy students with a knowledge base for clinical Pharmacogenetics. *Journal of American College of Clinical Pharmacy, in press*, 2020.
10. Keeley EC, Villaneuva M, Chen Y, **Gong Y**, Handberg EM, Smith SM, Pepine CJ, Cooper-DeHoff RM. Attended vs. unattended systolic blood pressure measurement: a randomized comparison in patients with cardiovascular disease. *J Clin Hypertens, in press*, 2020.
11. Mahmoodi BK, Tragante V, Kleber ME, Holmes MV, Schmidt AF, McCubrey RO, Howe LJ, Direk K, Allayee H, Baranova EV, Braund PS, Delgado GE, Eriksson N, Gijsberts CM, **Gong Y**, Hartiala J, Heydarpour M, Pasterkamp G, Kotti S, Kuukasjärvi P, Lenzini PA, Levin D, Lyytikäinen LP, Muehlschlegel JD, Nelson CP, Nikus K, Pilbrow AP, Wilson Tang WH, van der Laan SW, van Setten J, Vilmundarson RO, Deanfield J, Deloukas P, Dudbridge F, James S, Mordi IR, Teren A, Bergmeijer TO, Body SC, Bots M, Burkhardt R, Cooper-DeHoff RM, Cresci S, Danchin N, Doughty RN, Grobbee DE, Hagström E, Hazen SL, Held C, Hofer IE, Hovingh GK, Johnson JA, Kaczor MP, Kähönen M, Klungel OH, Laurikka JO, Lehtimäki T, Maitland-van der Zee AH, McPherson R, Palmer CN, Kraaijeveld AO, Pepine CJ, Sanak M, Sattar N, Scholz M, Simon T, Spertus JA, Stewart AFR,

- Szczeklik W, Thiery J, Visseren FLJ, Waltenberger J, Richards AM, Lang CC, Cameron VA, Åkerblom A, Pare G, März W, Samani NJ, Hingorani AD, Ten Berg JM, Wallentin L, Asselbergs FW, Patel RS. [Association of Factor V Leiden With Subsequent Atherothrombotic Events: A GENIUS-CHD Study of Individual Participant Data](#). *Circulation*. 2020 Aug 11;142(6):546-555. doi: 10.1161/CIRCULATIONAHA.119.045526. Epub 2020 Jul 13. PubMed PMID: 32654539.
12. Tantawy M, Pamittan FG, Singh S, **Gong Y**. Epigenetic changes associated with anthracycline-induced cardiotoxicity. *Clin Transl Sci*. 2020 Aug 8. doi: 10.1111/cts.12857. Online ahead of print. PMID: 32770710.
 13. Yang X, **Gong Y**, Waheed N, March K, Bian J, Hogan W, Wu Y. Identifying Cancer Patients with Risk of Heart Failure Using Machine Learning Methods. *AMIA Annu Symp Proc*. 2019:933-941. eCollection 2019. PubMed PMID: 32308890; PubMed Central PMCID: PMC7153053.
 14. Limdi NA, Cavallari LH, Lee CR, Hillegass WB, Holmes AM, Skaar T, Pisu M, Dillon C, Beitelshes AL, Empey PE, Duarte JD, Diaby V, **Gong Y**, Johnson JA, Graves JJ, Garbett S, Zhou Z, Peterson JF. Implementing GeNomics In practiCE (IGNITE) Network Pharmacogenetic Working Group (IGNITE-PGx). Cost-effectiveness of *CYP2C19*-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data. *Pharmacogenomics J*. 2020 Feb 11. doi: 10.1038/s41397-020-0162-5. [Epub ahead of print] PMID: 32042096
 15. Magvanjav O, Cooper-DeHoff RM, McDonough CW, **Gong Y**, Hogan WR, Johnson JA. Combination Antihypertensive Therapy Prescribing and Blood Pressure Control in a Real-World Setting. *Am J Hypertens*. 2019 Dec 19;. doi: 10.1093/ajh/hpz196. [Epub ahead of print] PubMed PMID: 31853537.
 16. Elgendy IY, Hill JA, Szady AD, **Gong Y**, Cooper-DeHoff RM, Pepine CJ. Systolic blood pressure, heart rate and outcomes in patients with coronary artery disease and heart failure: observations from the INternational VErapamil SR-Trandolapril Study (INVEST). *ESC Heart Fail*. 2019 Dec 15;. doi: 10.1002/ehf2.12534. [Epub ahead of print] PubMed PMID: 31840441.
 17. Archampong T, Ojewale O, Bears K, Chen Y, Lartey M, Sagoe KW, Obo-AKwa A, **Gong Y**, Langaee TY, Kwara A. Relationship between ABCC4 SNPs and hepatitis B virus suppression during tenofovir-containing antiretroviral therapy in patients with HIV/HBV coinfection. *J Acquir Immune Defic Syndr*. 2019 Dec 1;82(4):421-425. doi: 10.1097/QAI.0000000000002136. PubMed PMID: 31335591; PubMed Central PMCID: PMC6817383.
 18. Singh S, McDonough CW, **Gong Y**, Bailey KR, Boerwinkle E, Chapman AB, Gums JG, Turner ST, Cooper-DeHoff RM, Johnson JA. [Genome Wide Analysis Approach Suggests Chromosome 2 Locus to be Associated with Thiazide and Thiazide Like-Diuretics Blood Pressure Response](#). *Sci Rep*. 2019 Nov 21;9(1):17323. doi: 10.1038/s41598-019-53345-5. PubMed PMID: 31754133.

19. Shahin MH, Rouby NE, Conrado DJ, Gonzalez D, **Gong Y**, Lobmeyer MT, Beitelshes AL, Boerwinkle E, Gums JG, Chapman A, Turner ST, Pepine CJ, Cooper-DeHoff RM, Johnson JA. B2-adrenergic receptor gene affects the negative chronotropic effects of beta-blockers: evidence from three clinical studies. *J Clin Pharmacol*. 2019 Nov;59(11):1462-1470. doi: 10.1002/jcph.1443. Epub 2019 May 14. PubMed PMID: 31090079; PubMed Central PMCID: PMC6773496.
20. Cunninham PN, Wang Z, Grove ML, Cooper-DeHoff RM, Beitelshes AL, **Gong Y**, Gums JG, Johnson JA, Turner ST, Boerwinkle E, Chapman AB. Hypertensive APOL1 risk allele carriers demonstrate greater blood pressure reduction with angiotensin receptor blockade compared to low risk carriers. *PLoS One*. 2019;14(9):e0221957. doi: 10.1371/journal.pone.0221957. eCollection 2019. PubMed PMID: 31532792.
21. Singh S, El Rouby N, McDonough CW, **Gong Y**, Bailey KR, Boerwinkle B, Chapman AB, Gums JG, Turner ST, Cooper-DeHoff RM, Johnson JA. Genomic Association Analysis Reveals Variants Associated with Blood Pressure Response to Beta-Blockers in European Americans. *Clin Transl Sci*. 2019 Sep;12(5):497-504. doi: 10.1111/cts.12643. Epub 2019 Jun 4. PubMed PMID: 31033190; PubMed Central PMCID: PMC6742943.
22. Singh S, Warren HR, Hiltunen TP, Slavi E, El-Rouby N, Garofaltdou T, Fyhrust F, Kontula KK, Glorioso V, Zaninello R, Glorioso, Pepine CJ, Munroe PB, Beitelshes AL, Turner ST, Chapman AB, Boerwinkle E, Johnson JA, **Gong Y**, Cooper-DeHoff RM. Genome-wide meta-analysis of blood pressure response to B-blockers: Results from International Consortium of Antihypertensive Pharmacogenomics Studies (ICAPS). *J Am Heart Assoc*. 2019 Aug 20;8(16):e013115. doi: 10.1161/JAHA.119.013115. Epub 2019 Aug 19. PubMed PMID: 31423876.
23. Sava RI, Chen YE, Smith SM, **Gong Y**, Cooper-DeHoff RM, Keeley EC, Pepine CJ, Handberg EM. Risk and Blood Pressure Control Rates Across the Spectrum of Coronary Artery Disease in Hypertensive Women: An Analysis from The INternational VERapamil SR-Trandolapril STudy (INVEST). *J Womens Health (Larchmt)*. 2019 Aug 12;. doi: 10.1089/jwh.2018.7235. [Epub ahead of print] PubMed PMID: 31403360.
24. Smith DM, Weitzel KW, Elsey AR, Langae T, **Gong Y**, Wake DT, Duong BQ, Hagen M, Harle CA, Mercado E, Nagoshi Y, Newsom K, Wright A, Rosenberg EI, Starostik P, Clare-Salzler MJ, Schmidt SO, Fillingim RB, Johnson JA, Cavallari LH. CYP2D6 guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: A pragmatic clinical trial. *Genet Med*. 2019 Aug;21(8):1842-1850. doi: 10.1038/s41436-018-0431-8. Epub 2019 Jan 23. PubMed PMID: 30670877; PubMed Central PMCID: PMC6650382.
25. Harris TH, Wallace MR, Huang H, Li H, Mohiuddeen A, **Gong Y**, Kompotiati T, Harrison P, Aukhil I, Shaddox LM. Association of P2RX7 functional variants with localized aggressive periodontitis. *J Periodontal Res*. 2019 Jul 10;. doi: 10.1111/jre.12682. [Epub ahead of print] PubMed PMID: 31292966.

26. Mehanna M, Wang Z, **Gong Y**, McDonough CW, Beitelshes AL, Gums JG, Chapman AB, Schwartz GL, Bailey KR, Johnson JA, Turner ST, Cooper-DeHoff RM. Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension. *Am J Hypertens*. 2019 Jun 11;32(7):668-675. doi: 10.1093/ajh/hpz022. PubMed PMID: 30753254; PubMed Central PMCID: PMC6558666.
27. El Rouby N, McDonough CW, **Gong Y**, McClure LA, Mitchell BD, Horenstein RB, Talbert RL, Bradford Y, Crawford DC, Ritchie MD, Gitzendanner MA, Takahashi A, Tanaka T, Kubo Michiaki, Pepine CJ, Cooper-DeHoff RM, Benavente OR, Shuldiner AR, Johnson JA. Genome-wide Association Analysis of Common Genetic Variants of Resistant Hypertension. *Pharmacogenomics J*. 2019 Jun;19(3):295-304. doi: 10.1038/s41397-018-0049-x. Epub 2018 Sep 20. PubMed PMID: 30237584; PubMed Central PMCID: PMC6426691.
28. Chamberlain AM, **Gong Y**, MaAuliffe K, Bian J, Song W, Liton MF, Fonseca V, Price-Haywood E, Guhl Em King JB, Shah RU, Puro J, Shenkman E, Pawloski PA, Margolis KL, Hernandez A, Cooper-DeHoff RM. PCSK9 Inhibitor Use in the Real World: Data from the National Patient Centered Research Network (PCORNet). *J Am Heart Assoc*. 2019 May 7;8(9):e011246. doi: 10.1161/JAHA.118.011246. PubMed PMID: 31020929.
29. Yang G, Singh S, Chen Y, Hamadeh IH, Langaee T, McDonough CW, Holliday LS, Lamba J, Moreb JS, Katz J, **Gong Y**. Pharmacogenomics of Osteonecrosis of the Jaw. *Bone*. 2019 Apr 22. pii: S8756-3282(19)30146-2. doi: 10.1016/j.bone.2019.04.010. [Epub ahead of print] Review. PubMed PMID: 31022475.
30. Solayman MH, Langaee TY, **Gong Y**, Shahin MH, Turner ST, Chapman AB, Gums JJ, Boerwinkle E, Beitelshes AL, El-Hamamsy M, El-Wakeel L, Cooper-DeHoff RM, Badary OA, Johnson JA. Effect of Plasma MicroRNA on the Antihypertensive Response to beta-blocker in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Studies. *Eur J Pharm Sci*. 2019 Apr 1;131:93-98. doi: 10.1016/j.ejps.2019.02.013. Epub 2019 Feb 10. PubMed PMID: 30753892.
31. Patel RS, Schmidt AF, Tragante V, McCubrey RO, Holmes MV, Howe LJ, Direk K, Åkerblom A, Leander K, Virani SS, Kaminski KA, Muehlschlegel JD, Dubé MP, Allayee H, Almgren P, Alver M, Baranova EV, Behloul H, Boeckx B, Braund PS, Breitling LP, Delgado G, Duarte NE, Dufresne L, Eriksson N, Foco L, Gijsberts CM, **Gong Y**, Hartiala J, Heydarpour M, Hubacek JA, Kleber M, Kofink D, Kuukasjärvi P, Lee VV, Leiherer A, Lenzini PA, Levin D, Lyytikäinen LP, Martinelli N, Mons U, Nelson CP, Nikus K, Pilbrow AP, Ploski R, Sun YV, Tanck MWT, Tang WHW, Trompet S, van der Laan SW, Van Setten J, Vilmundarson RO, Viviani Anselmi C, Vlachopoulou E, Boerwinkle E, Briguori C, Carlquist JF, Carruthers KF, Casu G, Deanfield J, Deloukas P, Dudbridge F, Fitzpatrick N, Gigante B, James S, Lokki ML, Lotufo PA, Marziliano N, Mordi IR, Muhlestein JB, Newton-Cheh C, Pitha J, Saely CH, Samman-Tahhan A, Sandesara PB, Teren A, Timmis A, Van de Werf F, Wauters E, Wilde AAM, Ford I, Stott DJ, Algra A, Andreassi MG, Ardissino D, Arsenault BJ, Ballantyne CM, Bergmeijer TO, Bezzina CR, Body SC, Bogaty P, de Borst GJ, Brenner H,

Burkhardt R, Carpeggiani C, Condorelli G, Cooper-DeHoff RM, Cresci S, de Faire U, Doughty RN, Drexel H, Engert JC, Fox KAA, Girelli D, Hagström E, Hazen SL, Held C, Hemingway H, Hofer IE, Hovingh GK, Johnson JA, de Jong PA, Jukema JW, Kaczor MP, Kähönen M, Kettner J, Kiliszek M, Klungel OH, Lagerqvist B, Lambrechts D, Laurikka JO, Lehtimäki T, Lindholm D, Mahmoodi BK, Maitland-van der Zee AH, McPherson R, Melander O, Metspalu A, Pepinski W, Olivieri O, Opolski G, Palmer CN, Pasterkamp G, Pepine CJ, Pereira AC, Pilote L, Quyyumi AA, Richards AM, Sanak M, Scholz M, Siegbahn A, Sinisalo J, Smith JG, Spertus JA, Stewart AFR, Szczeklik W, Szpakowicz A, Ten Berg JM, Thanassoulis G, Thiery J, van der Graaf Y, Visseren FLJ, Waltenberger J, Van der Harst P, Tardif JC, Sattar N, Lang CC, Paré G, Brophy JM, Anderson JL, März W, Wallentin L, Cameron VA, Horne BD, Samani NJ, Hingorani AD, Asselbergs FW. Association of Chromosome 9p21 with Subsequent Coronary Heart Disease events: A GENIUS-CHD study of individual participant data. *Circ Genom Precis Med.* 2019 Mar 21. doi: 10.1161/CIRCGEN.119.002471. [Epub ahead of print] PubMed PMID: 30897348.

32. Patel R, Tragante V, Schmidt AF, McCubrey RO, Holmes MV, Howe LJ, Direk K, Åkerblom A, Leander K, Virani SS, Kaminski KA, Muehlschlegel JD, Allayee H, Almgren P, Alver M, Baranova EV, Behloul H, Boeckx B, Braund PS, Breitling LP, Delgado G, Duarte NE, Dubé MP, Dufresne L, Eriksson N, Foco L, Scholz M, Gijsberts CM, Glinge C, **Gong Y**, Hartiala J, Heydarpour M, Hubacek JA, Kleber M, Kofink D, Kotti S, Kuukasjärvi P, Lee VV, Leisherer A, Lenzini PA, Levin D, Lyytikäinen LP, Martinelli N, Mons U, Nelson CP, Nikus K, Pilbrow AP, Ploski R, Sun YV, Tanck MWT, Tang WHW, Trompet S, van der Laan SW, Van Setten J, Vilmundarson RO, Viviani Anselmi C, Vlachopoulou E, Al Ali L, Boerwinkle E, Briguori C, Carlquist JF, Carruthers KF, Casu G, Deanfield J, Deloukas P, Dudbridge F, Engström T, Fitzpatrick N, Fox K, Gigante B, James S, Lokki ML, Lotufo PA, Marziliano N, Mordi IR, Muhlestein JB, Newton-Cheh C, Pitha J, Saely CH, Samman-Tahhan A, Sandesara PB, Teren A, Timmis A, Van de Werf F, Wauters E, Wilde AAM, Ford I, Stott DJ, Algra A, Andreassi MG, Ardissino D, Arsenault BJ, Ballantyne CM, Bergmeijer TO, Bezzina CR, Body SC, Boersma EH, Bogaty P, Bots M, Brenner H, Brugts JJ, Burkhardt R, Carpeggiani C, Condorelli G, Cooper-DeHoff RM, Cresci S, Danchin N, de Faire U, Doughty RN, Drexel H, Engert JC, Fox KAA, Girelli D, Grobbee DE, Hagström E, Hazen SL, Held C, Hemingway H, Hofer IE, Hovingh GK, Jabbari R, Johnson JA, Jukema JW, Kaczor MP, Kähönen M, Kettner J, Kiliszek M, Klungel OH, Lagerqvist B, Lambrechts D, Laurikka JO, Lehtimäki T, Lindholm D, Mahmoodi BK, Maitland-van der Zee AH, McPherson R, Melander O, Metspalu A, Niemcunowicz-Janica A, Olivieri O, Opolski G, Palmer CN, Pasterkamp G, Pepine CJ, Pereira AC, Pilote L, Quyyumi AA, Richards AM, Sanak M, Siegbahn A, Simon T, Sinisalo J, Smith JG, Spertus JA, Stender S, Stewart AFR, Szczeklik W, Szpakowicz A, Tardif JC, Ten Berg JM, Tfelt-Hansen J, Thanassoulis G, Thiery J, Torp-Pedersen C, van der Graaf Y, Visseren FLJ, Waltenberger J, Weeke PE, Van der Harst P, Lang CC, Sattar N, Cameron VA, Anderson JL, Brophy JM, Paré G, Horne BD, März W, Wallentin L, Samani NJ, Hingorani AD, Asselbergs FW. Subsequent Event Risk in Individuals with Established Coronary Heart Disease: Design and Rationale of the GENIUS-CHD Consortium. *Circ Genom Precis Med.* 2019 Mar 21. doi: 10.1161/CIRCGEN.119.002470. [Epub ahead of print] PubMed PMID: 30896328.

33. Yang X, Bian J, **Gong Y**, Hogan WR, Wu Y. MADEX: A system for Detecting Medications, Adverse Drug Events and their Relations from Clinical Notes. *Drug Saf.* 2019 Jan 2. doi: 10.1007/s40264-018-0761-0. [Epub ahead of print] PubMed PMID: 30600484.
34. Smith SM, Gurka MJ, **Gong Y**, Handberg E, Pepine CJ, Cooper-DeHoff RM. Intensive versus Standard Systolic Blood Pressure Targets in Treatment-resistant Hypertension: A pooled Analysis of SPRINT and ACCORD-DBP Data. *Am J Med.* 2018 Dec;131(12):1463-1472.e7. doi: 10.1016/j.amjmed.2018.08.005. Epub 2018 Aug 22. PubMed PMID: 30142317; PubMed Central PMCID: PMC6279479.
35. Magvanjav O, Cooper-DeHoff RM, McDonough CW, **Gong Y**, Segal MS, Hogan WR, Johnson JA. Antihypertensive Therapy Prescribing Patterns and Correlates of Blood Pressure Control among Hypertensive Patients with Chronic Kidney Disease. *J Clin Hypertens (Greenwich).* 2018 Nov 14. doi: 10.1111/jch.13429. [Epub ahead of print] PubMed PMID: 30427124.
36. Cicali EJ, Blake K, **Gong Y**, Mougey EB, Al-Atrash H, Chambers N, Denham J, Evans J, George DE, Gomez R, Palomo P, Taufiq S, Johnson JA, Lima JJ, Franciosi JP. Novel implementation of genotype-guided proton pump inhibitor medication therapy in children: a pilot, randomized, multi-site pragmatic trial. *Clin Transl Sci.* 2018 Oct 20. doi: 10.1111/cts.12589. [Epub ahead of print] PubMed PMID: 30341969.
37. Singh S, Wang Z, Shahin M, Langaee TY, **Gong Y**, Turner ST, Chapman AB, Gums JG, McDonough CW, Bailey KR, Beitelshes AL, Cooper-DeHoff RM, Scherer S, Boerwinkle B, Johnson JA. Targeted Sequencing Identifies Missense Variant in the *BEST3* Gene Associated with Antihypertensive response to Hydrochlorothiazide. *Pharmacogenet Genomics.* 2018 Nov;28(11):251-255. doi: 10.1097/FPC.0000000000000353. PubMed PMID: 30289819.
38. Wazzan T, Kashtwari D, Almaden WF, **Gong Y**, Chen Y, Moreb J, Katz J. Radiographic Bone Loss and the Risk of Medication Related Osteonecrosis of the Jaw (MRONJ) in Multiple Myeloma Patients. *Spec Care Dentist.* 2018 Sep 8. doi: 10.1111/scd.12318. [Epub ahead of print] PubMed PMID: 30194738.
39. Kawaguchi-Suzuki M, Cusi, Bril F, **Gong Y**, Langaee TY, Frye RF. A Genetic Response Score for Pioglitazone Use in Patients with Nonalcoholic Steatohepatitis. *Front Pharmacol.* 2018;9(752). doi:[10.3389/fphar.2018.00752](https://doi.org/10.3389/fphar.2018.00752). eCollection 2018. PubMed PMID: 30065651; PubMed Central PMCID: PMC6056641.
40. Sa ACC, Webb A, **Gong Y**, McDonough CW, Shahin MH, Datta S, Langaee TY, Turner ST, Beitelshes AL, Chapman AB, Boerwinkle E, Gums JG, Scherer SE, Cooper-DeHoff RM, Sadee W, Johnson JA. Blood pressure Signature Genes and Blood Pressure Response to Thiazide Diuretics: Results from the PEAR and PEAR-2 Studies. *BMC Medical Genomics.* 2018 Jun 20;11(1):55. doi: 10.1186/s12920-018-0370-x. PubMed PMID: 29925376

41. Mosley S, Hick JK, Donovan K, Gopalan P, Schmit J, Starr J, Silver N, Portman DG, **Gong Y**, Langae TY, Clare-Salzler M, Starostik P, George TJ, McLeod H, Cavallari LH. Design and Rational for the Precision Medicine Guided Treatment for Cancer Pain Pragmatic Clinical Trial. *Contemp Clin Trials*. 2018 May;68:7-13. doi: 10.1016/j.cct.2018.03.001. Epub 2018 Mar 10. PubMed PMID: 29535047; PubMed Central PMCID: PMC5899651.
42. Cavallari LH, Franchi F, Rollini F, Been L, Rivas A, Agarwal M, Smith DM, Newsome K, **Gong Y**, Eley AR, Starostik P, Johnson JA, Angiolillo D. Clinical Implementation of Rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention. *J Transl Med*. 2018 Apr 11;16(1):92. doi: 10.1186/s12967-018-1469-8. PubMed PMID: 29642909.
43. McDonough CW, Magvanjav O, Sa ACC, El Rouby NM, Dave C, Deitchman AN, Kawaguchi-Suzuki M, Mei W, Shen Y, Singh R, Solayman M, Bailey KR, Boerwinkle E, Chapman AB, Gums JJ, Turner ST, Cooper-DeHoff RM, **Gong Y**, Johnson JA. Genetic Variants Influencing Plasma Renin Activity in Hypertensive Patients from the Pharmacogenomics Evaluation of Antihypertensive Responses (PEAR) Study. *Circ Genom Precis Med*. 2018 Apr;11(4):e001854. doi: 10.1161/CIRCGEN.117.001854. PubMed PMID: 29650764.
44. Shah C, **Gong Y**, Szady A, Sun Qian, Pepine CJ, Langae TY, Lucas AR, Moreb JS. Unanticipated cardiotoxicity due to targeted anticancer therapy in patients with hematologic malignancies: National history and risk factors. *Cardiovasc Toxicol*. 2018 Apr;18(2):184-191. doi: 10.1007/s12012-017-9429-8. PMID: 29022233.
45. Yu G, Wu D, **Gong Y**, Li G, Zhou HH. Conflicting meal recommendations for oral oncology drugs: pose risks to patient care? *Eur J Clin Pharmacol*. 2018 Jun;74(6):833-842. doi: 10.1007/s00228-018-2439-z. Epub 2018 Mar 13. PubMed PMID: 29536134.
46. **Gong Y**, Smith SM, Handberg EM, Pepine CJ, Cooper-DeHoff RM. Intensive Blood Pressure Lowering Reduces Adverse Cardiovascular Outcomes among Patients with high-normal glucose: an analysis of the Systolic Blood Pressure Intervention Trial database. *J Clin Hypertens* (Greenwich). 2018 Mar 13. doi: 10.1111/jch.13247. [Epub ahead of print] PubMed PMID: 29532983.
47. Singh S., McDonough C.W., **Gong Y**, Alghamdi W., Arwood M.J., Bargal S.A., Dumeny L., Wen-Yi L., Mehanna M., Stockard B., Yang G., de Oliveira F., Fredette N.C., Shahin M.H., Bailey K.R., Beitelshes A.L., Boerwinkle E., Chapman A.B., Gums J.G., Turner S.T., Cooper-DeHoff R.M., Johnson J.A. Genome wide association study identifies the *HMGCS2* locus to be associated with chlorthalidone induced glucose increase in hypertensive patients. *J Am Heart Assoc.*, 2018 Mar 9;7(6). pii: e007339. doi: 10.1161/JAHA.117.007339. PMID: 29523524
48. Shahin MH, Conrado DJ, Gonzalez D, **Gong Y**, Lobmeyer M, Cooper-DeHoff RM, Boerwinkle E, Turner ST, Chapman AB, Gums JG, Johnson JA. Genome-wide Association

Approach identified novel genetic predictors of Heart Rate Response to β -blockers. *J Am Heart Assoc.*, 2018 Feb 24;7(5). pii: e006463. doi: 10.1161/JAHA.117.006463. PMID: 29478026

49. Yang G, Hamadeh IS, Katz J, Riva A, Lakatos P, Bernadett B, Kosa J, Vaszilko M, Pelliccioni GA, Davis N, Langae TY, Moreb JS, **Gong Y**. *SIRT1/HERC4* Locus Associated with Bisphosphonate-induced Osteonecrosis of the Jaw: An Exome-wide Association Analysis. *J Bone Miner Res.*, 2018 Jan;33(1):91-98. doi: 10.1002/jbmr.3285. PubMed PMID: 28856724.
50. Weitzel K, Smith DM, Eley AR, Duong BQ, Burkely B, Clare-Salzler M, **Gong Y**, Higgins TA, Kong B, Langae TY, McDonough CW, Staley BJ, Vo TT, Wake DT, Cavallari LH, Johnson JA. Implementation of Standardized Clinical Processes for TPMT Testing in a Diverse Multidisciplinary Population: Challenges and Lessons Learned. *Clin Transl Sci.* 2018 Mar;11(2):175-181. doi: 10.1111/cts.12533. PubMed PMID: 29351371.
51. Cavallari LH, Lee CR, Beitelshes AL, Duarte JD, Voora D, Kimmel SE, Cooper-DeHoff RM, McDonough CW, **Gong Y**, Dave CD, Pratt VM, Alestock TD, Anderson RD, Alsip J, Ardati AK, Brott BC, Brown L, Chumnumwat S, Clare-Salzler MJ, Coons JC, Denny JC, Dillon C, Eley AR, Hamadeh I, Harada S, Hillegass WB, Hines L, Horenstein RB, Howell LA, Jeng LJ, Keleman MD, Lee YM, Magvanjav O, Montasser M, Nelson DR, Nutescu EA, Nwaba D, Rakyz RE, Palmer K, Peterson JF, Pollin TI, Quinn AH, Robinson SW, Schub J, Skaar TC, Smith DM, Sriramoju VB, Starostik P, Stys TP, Stevenson JM, Varunok N, Vesely MR, Wake D, Weck KE, Weitzel KW, Wilke RA, Willig J, Zhao RY, Kreutz RP, Stouffer GA, Empey PE, Limdi NA, Shuldiner AR, Winterstein AG, Johnson JA, on behalf of the IGNITE Network Pharmacogenetics Working Group. Multi-site Investigation of Outcomes with Implementation of CYP2C19-Genotype guided antiplatelet therapy after Percutaneous Coronary Intervention. *JACC Cardiovasc Interv* 2018 Jan 22;11(2):181-191. doi: 10.1016/j.jcin.2017.07.022. Epub 2017 Nov 1. PubMed PMID: 29102571; PubMed Central PMCID: PMC5775044.
52. Shahin M, **Gong Y**, Frye R, Rotroff D, Beitelshes AL, Baillie R, Chapman AB, Gums JG, Turner ST, Boerwinkle E, Motsinger-Reif A, Fiehn O, Cooper-DeHoff RM, Han X, Kaddurah-Daouk R, Johnson JA. Spingomyeline Metabolic Pathway Impacts Thiazide Diuretics Blood Pressure Response: Insights from Genomics, Metabolomics, and Lipidomics. *J Am Heart Assoc.*, 2017 Dec 29; 7(1): pii:e006656. PMID: 29288159
53. Huo T, Canepa R, Sura A, Modave F, **Gong Y**. Colorectal Cancer Stages Transcriptome Analysis. *PLoS One.* 2017 Nov 28;12(11):e0188697. doi: 10.1371/journal.pone.0188697. eCollection 2017. PubMed PMID: 29182684.
54. Sa ACC, Webb A, **Gong Y**, McDonough CW, Datta S, Langae TY, Turner ST, Beitelshes AL, Chapman AB, Boerwinkle E, Gums JG, Scherer SE, Cooper-DeHoff RM, Sadee W, Johnson JA. Whole Transcriptome Sequencing Analyses Reveal Molecular Markers of

Blood Pressure Response to Thiazide Diuretics. *Scientific reports*. 2017; 7(1):16068. PMID: 29167564.

55. Li G, Yu G, **Gong Y**. Proton Pump Inhibitors and Capecitabine Efficacy: Time-independent or Time-dependent Effect? *JAMA Oncol*. 2017 Nov 2. doi: 10.1001/jamaoncol.2017.3407. [Epub ahead of print] PubMed PMID: 29098270.
56. Magvanjav O, **Gong Y**, McDonough CW, Beitelshees AL, Gums JG, Bailey KR, Boerwinkle E, Chapman AB, Turner ST, Cooper-DeHoff RM, Johnson JA. Genetic Variants Associated With Uncontrolled Blood Pressure on Thiazide Diuretic/ β -Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and INVEST (International Verapamil-SR Trandolapril Study) Trials. *J Am Heart Assoc*. 2017 Nov 2;6(11). pii: e006522. doi: 10.1161/JAHA.117.006522. PubMed PMID: 29097388.
57. Mehanna M, **Gong Y**, McDonough CW, Beitelshees AL, Gums JG, Chapman AB, Johnson JA, Turner ST, Cooper-DeHoff RM. Blood Pressure Responses to Metoprolol and Chlorthalidone in Hypertensive European and African Americans. *J Clin Hypertens* (Greenwich). 2017 Sep 21. doi: 10.1111/jch.13094. [Epub ahead of print]. PMID: 28940643
58. Wokhlu A, Smith SM, **Gong Y**, Handberg EM, Elgendy IY, Bavry AA, Cooper-DeHoff RM, Pepine CJ. Mortality implications of lower archived diastolic blood pressure with lower achieved systolic pressures in Coronary Artery Disease: Long-term Mortality Results from the U.S. Cohort of International Verapamil SR Trandolapril Study (INVEST). *J Hypertens*. 2017 Sep 21. doi: 10.1097/HJH.0000000000001559. [Epub ahead of print]. PMID: 28938338.
59. Zewinger S, Kleber ME, Tragante V, McCubrey RO, Schmidt AF, Direk K, Laufs U, Werner C, Koenig W, Rothenbacher D, Mons U, Breitling LP, Brenner H, Jennings RT, Petrakis I, Triem S, Klug M, Filips A, Blankenberg S, Waldeyer C, Sinning C, Schnabel RB, Lackner KJ, Vlachopoulou E, Nygård O, Svingen GFT, Pedersen ER, Tell GS, Sinisalo J, Nieminen MS, Laaksonen R, Trompet S, Smit RAJ, Sattar N, Jukema JW, Groesdonk HV, Delgado G, Stojakovic T, Pilbrow AP, Cameron VA, Richards AM, Doughty RN, **Gong Y**, Cooper-DeHoff R, Johnson J, Scholz M, Beutner F, Thiery J, Smith JG, Vilmundarson RO, McPherson R, Stewart AFR, Cresci S, Lenzini PA, Spertus JA, Olivieri O, Girelli D, Martinelli NI, Leisher A, Saely CH, Drexel H, Mündlein A, Braund PS, Nelson CP, Samani NJ, Kofink D, Hofer IE, Pasterkamp G, Quyyumi AA, Ko YA, Hartiala JA, Allayee H, Tang WHW, Hazen SL, Eriksson N, Held C, Hagström E, Wallentin L, Åkerblom A, Siegbahn A, Karp I, Labos C, Pilote L, Engert JC, Brophy JM, Thanassoulis G, Bogaty P, Szczeklik W, Kaczor M, Sanak M, Virani SS, Ballantyne CM, Lee VV, Boerwinkle E, Holmes MV, Horne BD, Hingorani A, Asselbergs FW, Patel RS; GENIUS-CHD consortium., Krämer BK, Scharnagl H, Fliser D, März W, Speer T. Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. *Lancet Diabetes Endocrinol*. 2017 Jul;5(7):534-543. doi: 10.1016/S2213-8587(17)30096-7. Epub 2017 May 26. [Epub ahead of print] PubMed PMID: 28566218.

60. Magvanjav O, McDonough CW, **Gong Y**, McClure LA, Talbert RL, Horenstein RB, Mitchell BD, Shuldiner AR, Benavente OR, Johnson JA. Pharmacogenetic associations of beta-1 adrenergic receptor polymorphisms with cardiovascular outcomes in the Secondary Prevention of Small Subcortical Strokes (SPS3) trial. *Stroke*. 2017 May;48(5):1337-1343. pii: STROKEAHA.116.015936. doi: 10.1161/STROKEAHA.116.015936. Epub 2017 Mar 28. PubMed PMID: 28351962; PubMed Central PMCID: PMC5404951.
61. Miller K, Branco-de-Almeida LS, Wolf Sandra, Hovencamp N, Treloar T, Harrison P, Aukhil I, **Gong Y**, Shaddox LM. Long-term Clinical Response to Treatment and Maintenance of Localized Aggressive Periodontitis. *J Clin Periodontol.*, 2017 Feb;44(2):158-168. doi: 10.1111/jcpe.12640. PubMed PMID: 27767222; PubMed Central PMCID: PMC5303544.
62. Shahin MH, Sa AC, Webb A, **Gong Y**, Langae TY, McDonough CW, Riva A, Beitelshes AL, Chapman AB, Gums JG, Turner ST, Boerwinkle E, Scherer SE, Sadee W, Cooper-DeHoff RM, and Johnson JA. Genome Wide Prioritization and Transcriptomics Reveal Novel Signatures Associated with Thiazide Diuretics Blood Pressure Response. *Circ Cardiovasc Genet*. 2017 Jan;10(1). pii: e001404. doi:10.1161/CIRCGENETICS.116.001404. PubMed PMID: 28115488. PubMed Central PMCID: PMC5298887.
63. Salvi E, Wang Z, Rizzi F, **Gong Y**, McDonough CW, Padmanabhan S, Hiltunen TP, Lanzani C, Zaninello R, Chittani M, Bailey KR, Barcella M, Chapman AB, Johnson JA, Dominiczak AF, Kontula KK, Manunta P, Glorioso N, Barlassina C, Cusi D, Boerwinkle R, Cooper-DeHoff RM, Turner ST. Genome-wide and Gene-based Meta-Analyses to identify loci influencing antihypertensive response to hydrochlorothiazide. *Hypertension*. 2017 Jan;69(1):51-59. doi: 10.1161/HYPERTENSIONAHA.116.08267. PubMed PMID: 27802415. PubMed Central PMCID: PMC5145728.
64. Elgendy IY, Bavry AA, **Gong Y**, Handberg EM, Cooper-DeHoff RM, Pepine CJ. Long-term mortality in a cohort of hypertensive patients with coronary artery disease: Results from the INternational VErapamil/Trandolapril STudy. *Hypertension*. 2016 Nov;68(5):1110-1114. PubMed PMID: 27620390; PubMed Central PMCID: PMC5063713.
65. Smith MS, Huo T, **Gong Y**, Handberg EM, Gulati M, Merz NB, Pepine CJ, Cooper-DeHoff RM. Mortality and Cardiovascular risk associated with apparent treatment-resistant hypertension among women. *J Womens Health (Larchmt)*. 2016 Oct;25(10):996-1003 PubMed PMID: 27224417; PubMed Central PMCID: PMC5069707.
66. Weng L, **Gong Y**, Culver J, Gardell SJ, Petucci C, Morse AM, Frye RF, Turner ST, Chapman AB, Boerwinkle E, Gums JG, Beitelshes AL, Borum PR, Johnson JA, Garrett TJ, McIntyre LM, Cooper-DeHoff RM. Presence of Arachidonoyl-Carnitine is Associated with Adverse Cardiometabolic Responses in Hypertensive Patients Treated with Atenolol. *Metabolomics* (Los Angel). 2016 Oct;12(10). pii: 160. doi: 10.1007/s11306-016-1098-2. PubMed PMID: 28217401.

67. Chang SW, McDonough CW, **Gong Y**, Johnson TA, Tsunoda T, Gamazon ER, Perera MA, Takahashi, A, Tanaka T, Kubo M, Pepine CJ, Johnson JA, Cooper-DeHoff RM. Genome-wide Association study identified Pharmacogenomic Loci Associated with Antihypertensive Treatment-Related New-Onset Diabetes. *Pharmacogenomics J*. 2016 Sep 27. doi: 10.1038/tpj.2016.67. PMID: 27670767; PubMed Central PMCID: PMC5368017.
68. Shahin MH, **Gong Y**, McDonough CW, Rotroff DM, Beitelshes AL, Garrett T, Gums JG, Motsinger-Reif A, Chapman AB, Turner ST, Boerwinkle E, Frye RF, Oliver F, Cooper-DeHoff RM, Kaddurah-Daouk R, and Johnson JA. A Genetic Response Score for Hydrochlorothiazide Use: Insights from Genomics and Metabolomics Integration. *Hypertension*, 2016 Sep;68(3):621-9. PMID: 27381900
69. De Oliveria FA, Shahin MH, **Gong Y**, McDonough CW, Beitelshes AL, Gums JJ, Chapman AB, Boewinkle E, Turner ST, Frye RF, Fiehn O, Kaddurah-Daouk R, Johnson JA, Cooper-DeHoff RM. Novel Plasma Biomarker of Atenolol-Induced Hyperglycemia identified through a metabolomics-Genomics Integrative Approach. *Metabolomics* (Los Angel). 2016 Aug;12. pii: 129. doi: 10.1007/s11306-016-1076-8. PubMed PMID: 28217400; PubMed Central PMCID: PMC5310671.
70. Zhu HJ, Langaee TY, **Gong Y**, Wang X, Pepine CJ, Cooper-DeHoff RM, Johnson JA, Markowitz JS. No association between the CES1P1 variant -816A>C with hepatic carboxylesterase 1 expression and activity and antihypertensive effect of trandolapril. *Eur J Clin Pharmacol*. 2016 Jun;72(6):681-7. doi: 10.1007/s00228-016-2029-x. Epub 2016 Feb 26. PubMed PMID: 26915813; PubMed Central PMCID: PMC4865408.
71. Hoh BL, **Gong Y**, Waters M, Royster A, Sheehan T, Burkley B, McDonough CW, Mocco J, Zuckerman S, Ingram C, Shaffer CM, Denny J, Brilliant M, Kitchner T, Roden D, Johnson JA. *CYP2C19* and *CES1* Polymorphisms and Efficacy of Aspirin and Clopidogrel Dual Antiplatelet Therapy in Patients with Symptomatic Intracranial Atherosclerotic Disease. *J Neurosurg*. 2016 Jun;124(6):1746-51. doi: 10.3171/2015.6.JNS15795. Epub 2015 Nov 20. PubMed PMID: 26587656; PubMed Central PMCID: PMC4915569.
72. Chang SW, **Gong Y**, McDonough CW, N. Nasiri Kenari, T. Langaee, A.L. Beitelshes, J.G. Gums, A.B. Chapman, S.T. Turner, J.A. Johnson, Cooper-DeHoff RM. Melatonin Pathway and Atenolol-Related Glucose Dysregulation – Is there a Correlation? *Clin Transl Sci*. 2016 Apr;9(2):114-22. PubMed PMID: 26946962; PubMed Central PMCID: PMC4915567.
73. **Gong Y**, Wang Z, Beitelshes AL, McDonough CW, Langaee TY, Hall K, Schmidt SO, Curry RW, Gums JG, Bailey KR, Boerwinkle E, Chapman AB, Turner ST, Cooper-DeHoff RM, Johnson JA. Pharmacogenomic Genome-wide Meta-analysis of blood pressure response to beta-blockers in hypertensive African Americans. *Hypertension*. 2016 Mar;67(3):556-63. PubMed PMID: 26729753; PubMed Central PMCID: PMC4752391.
74. Khalil BM, Shahin MH, Langaee TY, Shaalan MF, **Gong Y**, Hammad LN, Al-Mesallamy HO, Hamdy NM, El-Hammady WA, Johnson JA. Genetic and Non-genetic factors among

clopidogrel efficacy in Egyptian population. *Clin Transl Sci*, 2016 Jan 12. doi: 10.1111/cts.12383. PubMed PMID: 26757134; PubMed Central PMCID: PMC4760893.

75. Zhang X, Hamadeh IS, Song S, Katz J, Moreb JS, Langaee TY, Lesko LJ, **Gong Y**. Osteonecrosis of the Jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS). *J Bone Miner Res*. 2016 Feb;31(2):336-40. PubMed PMID: 26288087
76. Prabhakaran S, Kim K, **Gong Y**, Hendeles L. Long Term Variability in Exhaled Nitric Oxide Measurements. *J Allergy Clin Immunol Pract*. 2016 Jan-Feb;4(1):147-148.e1. PMID: 26563669
77. Rotroff DM, Shahin MH, Gurley S, Zhu H, Motsinger-Reif A, Meisner M, Beitelshes AL, Fiehn O, Johnson JA, El-Badawi M, Frye RF, **Gong Y**, Weng L, Cooper-DeHoff RM, Kaddurah-Daouk RF. Pharmacometabolomic Assessment of Atenolol and Hydrochlorothiazide Treatment Reveal Novel Drug Response Phenotypes. *CPT Pharmacometrics Syst Pharmacol*. 2015 Nov;4(11):669-79. doi: 10.1002/psp4.12017. Epub 2015 Oct 29. PubMed PMID: 26783503.
78. **Gong Y**, McDonough CW, Beitelshes AL, Rouby NE, Hiltunen TP, O'Connell JR, Padmanabhan S, Langaee TY, Hall K, Schmidt SO, Curry RW Jr, Gums JG, Donner KM, Kontula KK, Bailey KR, Boerwinkle E, Takahashi A, Tanaka T, Kubo M, Chapman AB, Turner ST, Pepine CJ, Cooper-DeHoff RM, Johnson JA. *PTPRD* gene associated with blood pressure response to atenolol and resistant hypertension. *J Hypertens*. 2015 Nov;33(11):2278-85. PubMed PMID: [26425837](#); PubMed Central PMCID: PMC4788379.
79. Feild C, Belgado B, Dougherty J, Doering P, **Gong Y**. The Use of Application based Learning Techniques in a College of Pharmacy Based Biostatistics Course. *Currents in Pharmacy Teaching and Learning*. 2015;7:599-605
80. Chittani M, Zaniello R, Lanzani C, Frau F, Ortu MF, Slavi E, Fresu G, Citterio L, Braga D, Piras DA, Carpini SD, Velayutham D, Simonini M, Argiolas G, Possoli S, Troffa C, Glorioso V, Knotula K, Hiltunen TP, Donner KM, Turner ST, Boerwinkel E, Chpaman AB, Padmanaghan S, Dominiczak AF, Melander O, Johnson JA, Cooper-DeHoff RM, **Gong Y**, Manunta P, Cusi D, Glorioso N, Barlassina C. TET2 and CSMD1 genes affect systolic blood pressure response to hydrochlorothiazide in never treated essential hypertensives. *J Hypertens*. 2015 Jun;33(6):1301-9. PubMed PMID: 25695618.
81. Weng L, Eoin Q, **Gong Y**, Beitelshes AL, Shahin MH, Turner ST, Chapman AB, Gums JG, Johnson JA, Frye RF, Garrett TJ, Cooper-DeHoff RM. Association of Branched and Aromatic Amino Acids Levels with Metabolic Syndrome and Impaired Fasting glucose in Hypertensive Patients. *Metab Syndr Relat Disord*. 2015 Jun;13(5):195-202. doi: 10.1089/met.2014.0132. Epub 2015 Feb 9. PubMed PMID: 25664967.
82. McDonough CW, McClure LA, Mitchell BD, **Gong Y**, Horenstein RB, Lewis JP, Field TS, Talbert RL, Benavente OR, Johnson JA, Shuldiner AR. CYP2C19 Metabolizer Status and

Clopidogrel Efficacy in The Secondary Prevention of Small Subcortical Strokes (SPS3) Study. *J Am Heart Assoc.* 2015 May 27;4(6). pii: e001652. doi: 10.1161/JAHA.114.001652. PubMed PMID: 26019129.

83. Hamadeh IS, Ngwa BA, **Gong Y**. Drug induced osteonecrosis of the jaw. *Cancer Treat Rev.* 2015; 41 (5), 455-464. PubMed PMID: 25913713.
84. Bavry AA, **Gong Y**, Handberg EM, Cooper-DeHoff RM, Pepine CJ. Impact of Aspirin According to Type of Ischemic Heart Disease: Insight from a Large International Database. *Am J Med.* 2015 Feb;128(2):137-43. PMID: 25447610
85. Hiltunen TP, Donner K, Sarin A, Saarela J, Ripatti S, Chapman A, Gums JG, **Gong Y**, Cooper-DeHoff RM, Frau F, Glorioso V, Zaninello R, Slavi E, Florioso N, Boerwinkle E, Turner ST, Johnson JA, Kontula K. Pharmacogenomics of Hypertension: A genome-wide placebo-controlled cross-over study, using four classes of antihypertensive drugs. *J Am Heart Assoc.* 2015;4:e001521 doi: 10.1161/JAHA.114.001521
86. Denardo SJ, **Gong Y**, Keltai M, Szirmai LA, Farsang C, Mancina G, Bavry AA, Cooper-DeHoff RM, Handberg EM, Pepine CJ. Effects of Verapamil SR and Atenolol on 24-Hour Blood Pressure and Heart Rate in Hypertension Patients with Coronary Artery Disease: An International Verapamil SR-Trandolapril Ambulatory Monitoring Substudy. *PLoS One.* 2015 Apr 2;10(4):e0122726. PubMed PMID: 25835002
87. Fontana V*, McDonough CW*, **Gong Y**, El Rouby NM, Sá ACC, Taylor KD, Chen Y-D I, Gums JG, Chapman AB, Turner ST, Pepine CJ, Johnson JA, Cooper-DeHoff RM. Large-Scale Gene-centric Analysis Identifies Polymorphisms for Resistant Hypertension. *These authors contributed equally to this work. *J Am Heart Assoc.* 2014 Nov 10;3(6). pii: e001398. PMID: 25385345.
88. Moore MJ*, **Gong Y***, Hou W, Hall K, Schmidt SO, Curry RW, Beitelshes AL, Chapman AB, Turner ST, Schwartz GL, Bailey K, Boerwinkle E, Gums JG, Cooper-DeHoff RM, Johnson JA. Predictors for Glucose Change in Hypertensive Participants Following Short-term Treatment with Atenolol or Hydrochlorothiazide. *These authors contributed equally to this work. *Pharmacotherapy.* 2014 Nov;34(11):1132-40. PMID: 25202885.
89. Vandell AG, McDonough CW, **Gong Y**, Langae TY, Lucas AM, Chapman AB, Gums JG, Beitelshes AL, Bailey KR, Johnson RJ, Boerwinkle E, Turner ST, Cooper-DeHoff RM, Johnson JA. Hydrochlorothiazide-induced Hyperuricemia in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study. *J Intern Med.* 2014 Nov;276(5):486-97. PMID: 24612202
90. Bangalore S, **Gong Y**, Cooper-DeHoff RM, Pepine CJ, Messerli FH. 2014 Eighth Joint National Committee Panel Recommendation for Blood Pressure Targets Revisited: Results from the INVEST Study. *JACC.* 2014; 64 (8): 784-93. PMID: 25145522

91. Hamadeh IS, Langaee TY, Dwividi R, Garcia S, Burkley BM, Chapman AB, Gums JG, Turner ST, **Gong Y**, Cooper-DeHoff RM, Johnson JA. Impact of CYP2D6 Polymorphisms on Clinical Efficacy and Tolerability of Immediate Release Metoprolol Tartrate. *Clin Pharmacol Ther.* 2014 Aug;96(2):175-81. PMID: 24637943
92. Karnes JH, **Gong Y**, Arwood MJ, Gums JG, Hall K, Limacher MC, Johnson JA, and Cooper-DeHoff RM. Alteration in fasting glucose after prolonged treatment with a thiazide diuretic. *Diabetes Res Clin Pract.* 2014. Jun;104(3):363-9. PMID: 24794890
93. Yoneyama S, Guo Y, Lanktree MB, Barnes MR, Elbers CC, Karczewski KJ, Padmanabhan S, Bauer F, Baumert J, Beitelshes A, Berenson GS, Boer JM, Burke G, Cade B, Chen W, Cooper-Dehoff RM, Gaunt TR, Gieger C, **Gong Y**, Gorski M, Heard-Costa N, Johnson T, Lamonte MJ, McDonough C, Monda KL, Onland-Moret NC, Nelson CP, O'Connell JR, Ordovas J, Peter I, Peters A, Shaffer J, Shen H, Smith E, Speilotes L, Thomas F, Thorand B, Verschuren WM, Anand SS, Dominiczak A, Davidson KW, Hegele RA, Heid I, Hofker MH, Huggins GS, Illig T, Johnson JA, Kirkland S; the Look AHEAD Research Group, König W, Langaee TY, McCaffery J, Melander O, Mitchell BD, Munroe P, Murray SS, Papanicolaou G, Redline S, Reilly M, Samani NJ, Schork NJ, van der Schouw YT, Shimbo D, Shuldiner AR, Tobin MD, Wijmenga C, Yusuf S; the GIANT Consortium; the CARE IBC Consortium, Hakonarson H, Lange LA, Demerath EW, Fox CS, North KE, Reiner AP, Keating B, Taylor KC. Gene-centric meta-analyses for central adiposity traits in up to 57,412 individuals of European descent confirm known loci and reveal several novel associations. *Hum Mol Genet.* 2014 May 1;23(9):2498-510. PMID: 24345515.
94. Cooper-DeHoff RM, Hou W, Weng L, Baillie R, Beitelshes AL, **Gong Y**, Shahin MHA, Turner ST, Chapman AB, Gums JG, Boyle S, Zhu H, Wikoff RW, Boerwinkle E, Feine O, Frye R, Kaddurah-Daouk R, Johnson JA. Is a Diabetes-linked Amino Acid Signature Associated with Beta Blocker-induced Impaired Fasting Glucose? *Circ Cardiovasc Genet.* 2014 Apr 1;7(2):199-205. PMID: 24627569.
95. Chapman AB, Cotsonis G, Parekh V, Schwartz GL, **Gong Y**, Bailey KR, Turner ST, Gums JG, Beitelshes AL, Cooper-DeHoff R, Boerwinkle E, Johnson JA. Night Blood Pressure Responses to Atenolol and Hydrochlorothiazide in Black and White Patients with Essential Hypertension. *Am J Hypertens.* 2014 Apr;27(4):546-54. PMID: 23886594
96. Tragante V, Barnes MR, Ganesh SK, Lanktree MB, Guo W, Franceschini N, Smith EN, Johnson T, Holmes MV, Padmanabhan S, Karczewski KJ, Almoguera B, Barnard J, Baumert J, Chang YP, Elbers CC, Farrall M, Fischer ME, Gaunt TR, Gho JM, Gieger C, Goel A, **Gong Y**, Isaacs A, Kleber ME, Leach IM, McDonough CW, Meijs MF, Melander O, Nelson CP, Nolte IM, Pankratz N, Price TS, Shaffer J, Shah S, Tomaszewski M, van der Most PJ, Van Iperen EP, Vonk JM, Witkowska K, Wong CO, Zhang L, Beitelshes AL, Berenson GS, Bhatt DL, Brown M, Burt A, Cooper-Dehoff RM, Connell JM, Cruickshanks KJ, Curtis SP, Davey-Smith G, Delles C, Gansevoort RT, Guo X, Haiqing S, Hastie CE, Hofker MH, Hovingh GK, Kim DS, Kirkland SA, Klein BE, Klein R, Li YR, Maiwald S, Newton-Cheh C, O'Brien ET, Onland-Moret NC, Palmas W, Parsa A, Penninx BW, Pettinger M, Vasan RS, Ranchalis JE, M Ridker P, Rose LM, Sever P, Shimbo D, Steele L,

Stolk RP, Thorand B, Trip MD, van Duijn CM, Verschuren WM, Wijmenga C, Wyatt S, Young JH, Zwinderman AH, Bezzina CR, Boerwinkle E, Casas JP, Caulfield MJ, Chakravarti A, Chasman DI, Davidson KW, Doevendans PA, Dominiczak AF, Fitzgerald GA, Gums JG, Fornage M, Hakonarson H, Halder I, Hillege HL, Illig T, Jarvik GP, Johnson JA, Kastelein JJ, Koenig W, Kumari M, März W, Murray SS, O'Connell JR, Oldehinkel AJ, Pankow JS, Rader DJ, Redline S, Reilly MP, Schadt EE, Kottke-Marchant K, Snieder H, Snyder M, Stanton AV, Tobin MD, Uitterlinden AG, van der Harst P, van der Schouw YT, Samani NJ, Watkins H, Johnson AD, Reiner AP, Zhu X, de Bakker PI, Levy D, Asselbergs FW, Munroe PB, Keating BJ. Gene-centric meta-analysis in 87,736 individuals of European ancestry identifies multiple blood pressure related loci. *Am J Hum Genet.* 2014 Mar 6;94(3):349-60. PubMed PMID: 24560520.

97. Rosenwasser R, Shah NK, Smith SM, Wen X, **Gong Y**, Gums JG, Nichols WW, Chapman AB, Boerwinkle E, Johnson JA, Epstein B. Baseline Predictors of Central Aortic Blood Pressure: A PEAR Substudy. *J Am Soc Hypertens.* 2014;8(3):152-8. PMID: 24629400
98. Smith SM, **Gong Y**, Handberg EM, Messerli FH, Bakris GL, Ahmed A, Bavry AA, Pepine CJ, Cooper-DeHoff RM. Clinical Outcomes and Predictors of Resistant Hypertension Among Patients with Coronary Artery Disease. *J Hypertens.* 2014 Mar;32(3):635-43. PMID: 24299915.
99. **Gong Y**, McDonough CW, Beitelshes AL, O'Connell JR, Karnes JH, Turner ST, Chapman AB, Gums JG, Bailey KR, Boerwinkle E, Johnson JA, Cooper-DeHoff RM. *PROX1* Gene Variant is Associated with Glucose Change after Antihypertensive Treatment. *Pharmacotherapy.* 2014 Feb;34(2):123-30. PMID: 24122840
100. Karnes JH, **Gong Y**, Pacanowski MA, McDonough CW, Arwood M, Langaee TY, Pepine CJ, Johnson JA, Cooper-DeHoff RM. Impact of *TCF7L2* single nucleotide polymorphisms on Hydrochlorothiazide-induced diabetes. *Pharmacogenet Genomics.* 2013 Dec;23(12):697-705. PMID: 24128935.
101. McDonough CW, Gillis NK, Alsultan A, Chang S, Lang JE, Shahin MH, Suzuki-Kawaguchi M, Buford TW, Langaee TY, Gums JG, Chapman AB, Turner ST, Cooper-DeHoff RM, **Gong Y**, Johnson JA. Atenolol Induced HDL-C Change in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study. *PLoS One.* 2013; 8(10):e76984. PMID: 24116192
102. Bavry AA, Kumbhani DJ, **Gong Y**, Handberg EM, Cooper-DeHoff RM, Pepine CJ. Simple Integer Risk Score to Determine Prognosis of Patients with Hypertension and Chronic Stable Coronary Disease. *J Am Heart Assoc.* 2013 Aug 15; 2 (4):e000205. PMID: 23948642
103. Turner ST, Boerwinkle E, O'Connell J, Bailey KR, **Gong Y**, Chapman AB, McDonough CW, Beitelshes AL, Schwartz GL, Gums JG, Padmanabhan S, Hiltunen TP, Citterio L, Donner KM, Hedner T, Lanzani C, Melander O, Saarela J, Ripatti S, Wahlstand B, Manunta P, Kontula K, Dominiczak AF, Cooper-DeHoff RM, Johnson JA. Genomic Association

Analyses of Common Variants Influencing Antihypertensive Response to Hydrochlorothiazide. *Hypertension*. 2013 Aug;62(2):391-7. PMID: 23753411.

104. Winchester DE, Cooper-Dehoff RM, **Gong Y**, Handberg EM, Pepine CJ. Mortality implications of angina and blood pressure in hypertensive patients with coronary artery disease: new data from extended follow-up of the INternational VErapamil/Trandolapril Study (INVEST). *Clin Cardiol*. Clin Cardiol. 2013 Aug;36(8):442-7. PMID: 23720247.
105. McDonough CW, **Gong Y**, Padmanabhan S, Burkley B, Langaee TY, Melander O, Pepine CJ, Dominiczak AF, Cooper-DeHoff RM, Johnson JA. Pharmacogenomic association of non-synonymous SNPs in *SIGLEC12*, *A1BG*, and the Selectin Region and Cardiovascular Outcomes. *Hypertension*. 2013 Jul;62(1):48-54. PMID: 23690342.
106. Lima JJ, Lang JE, Mougey EB, Blake KB, **Gong Y**, Holbrook J, Wise RW, Teague WG. Association of *CYP2C19* Polymorphisms on Lansoprazole-Associated Respiratory Adverse Effects in Children. *J Pediatr*. 2013 Sep;163(3):686-91. PMID: 23623526
107. Wikoff WR, Frye R, Zhu H, **Gong Y**, Boyle S, Churchill E, Cooper-DeHoff RM, Beitelshes AL, Lane A, Chapman AB, Turner ST, Fiehn O, Johnson JA, Kaddurah-Daouk R. Pharmacometabolomics Reveals Racial Differences in Response to Atenolol Treatment. *PLOS ONE*, 2013; 8(3):e57639. PMID: 23536766.
108. Del-Aguila JL, Beitelshes AL, Cooper-Dehoff RM, Chapman AB, Gums JG, Bailey K, **Gong Y**, Turner ST, Johnson JA, Boerwinkle E. Genome-wide association analyses suggest *NELL1* influences adverse metabolic Response to HCTZ in African Americans. *Pharmacogenomics J*. 2014 Feb;14(1):35-40. PMID: 23400010.
109. Lewis JP, Ryan K, O'Connell JR, Horenstein RB, Damcott CM, Gibson Q, Pollin TI, Mitchell BD, Beitelshes AL, Pakzy R, Parsa A, Tantry US, Bliden KP, Post W, Faraday N, Herzog W, **Gong Y**, Pepine CJ, Johnson JA, Gurbel PA, Shuldiner AR. Genetic Variants in Platelet Endothelial Aggregation Receptor -1 (*PEAR1*) is Associated with Platelet Aggregation and Cardiovascular Outcomes. *Circ Cardiovasc Genet*. 2013 Apr;6(2):184-92. [Epub ahead of print] PMID: 23392654.
110. Ganesh S, Tragante V, Guo W, Guo Y, Lanktree MB, Smith EN, Johnson T, Almoguera Castillo B, Barnard J, Baumert J, Chang YPC, Elbers CC, Farrall M, Fischer ME, Franceschini N, Gaunt TR, Gho JMIH, Gieger C, **Gong Y**, Isaacs A, Kleber ME, Mateo Leach I, McDonough CW, Meijis MFL, Mellander O, Molony CM, Nolte IM, Padmanabhan S, Price TS, Rajagopalan R, Shaffer J, Shah S, Shen H, Soranzo N, van der Mos PG, Van Iperen EPA, van Setten J, Vonk JM, Zhang L, Beitelshes AL, Berenson GS, Bhatt DL, Boer JMA, Boerwinkle E, Burkley B, Burt A, Chakravarti A, Chen W, Cooper-DeHoff RM, Curtis SP, Dreisbach A, Duggan D, Ehret GB, Fabsitz R, Fornage M, Fox E, Furlong CE, Gansevoort RT, Hofker MH, Hovingh GK, Kirkland SA, Kottke-Marchant K, Kutlar A, LaCroix AZ, Langaee TY, Li YR, Lin H, Liu K, Maiwald S, Malik R, METASTROKE, Murugesan G, Newton-Cheh C, O'Connell JR, Onland-Moret NC, Ouwehand WH, Palmas W, Penninx BW, Pepine CJ, Pettinger M, Polak J, Ramachandran VS, Ranchalis J, Redline

- S, Ridker PM, Rose LM, Scharnagl H, Schork NJ, Shimbo D, Shuldiner AR, Srinivasan SR, Stolk RP, Taylor HA, Thorand B, Trip MD, van Duijn CM, Vasan R, Verschuren WM, Wijmenga C, Winkelmann BR, Wyatt S, Young JH, Boehm BO, Caulfield MJ, Chasman DI, Davidson KW, Doevendans PA, FitzGerald GA, Gums JG, Hakonarson H, Hillege HL, Illig T, Jarvik GP, Johnson JA, Kastelein JJP, Koenig W, LifeLines Cohort Study, März W, Mitchell BD, Murray SS, Oldehinkel AJ, Rader DJ, Reilly MP, Reiner AP, Schadt EE, Silverstein RL, Snieder H, Stanton AV, Uitterlinden AG, van der Harst P, van der Schouw YT, Samani N J, Johnson AD, Munroe PB, de Bakker PIW, Zhu X, Levy D, Keating BJ, Asselbergs FA. Loci influencing blood pressure identified using a cardiovascular gene-centric array. *Hum Mol Genet.* 2013 Apr 15;22(8):1663-78. PMID: 23303523
111. McDonough CW, Burbage SE, Duarte JD, **Gong Y**, Langaee TY, Turner ST, Gums JG, Chapman AB, Bailey KR, Beitelshes AL, Boerwinkle E, Pepine CJ, Cooper-DeHoff RM, Johnson JA. Association of variants in *NEDD4L* with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics. *J Hypertens.* 2013 Apr;31(4):698-704. PMID: 23353631.
112. Chan K, Patel RS, Newcombe P, Nelson CP, Qasim A, Epstein SE, Burnett S, Vaccarino VL, Zafari AM, Shah SH, Anderson JL, Carlquist JF, Hartiala J, Allayee H, Hinohara K, Lee BS, Erl A, Ellis KL, Goel A, Schaefer AS, El Mokhtari NE, Goldstein BA, Hlatky MA, Go AS, Shen GQ, **Gong Y**, Pepine C, Laxton RC, Whittaker JC, Tang WH, Johnson JA, Wang QK, Assimes TL, Nöthlings U, Farrall M, Watkins H, Richards AM, Cameron VA, Muendlein A, Drexel H, Koch W, Park JE, Kimura A, Shen WF, Simpson IA, Hazen SL, Horne BD, Hauser ER, Quyyumi AA, Reilly MP, Samani NJ, Ye S. Association Between the Chromosome 9p21 Locus and Angiographic Coronary Artery Disease Burden: A Collaborative Meta-Analysis. *J Am Coll Cardiol.* 2013 Mar 5;61(9):957-70. PMID: 23352782.
113. Lang JE., Mougey EB, Allayee H, Blake KB, Lockey R, **Gong Y**, Hossain J, Killen K, Lima JJ. Nutrigenetic response to omega-3 fatty acids in obese asthmatics (NOOA): Rationale and methods. *Contemp Clin Trials.* 2013 Mar;34(2):326-35. PMID: 23298524.
114. Le MT, Lobmeyer MT, Campbell M, Cheng J, Wang Z, Turner ST, Chapman AB, Boerwinkle E, Gums JG, **Gong Y**, Johnson RJ, Johnson JA. Impact of genetic polymorphisms of *SLC2A2*, *SLC2A5*, and *KHK* on metabolic and hemodynamic phenotypes in hypertensive individuals. *PLoS ONE* 2013. 8(1): e52062. PMID: 23341889
115. Karnes JH, Langaee TY, McDonough CW, Chang S, Ramos M, Catlin JR, Casanova O, **Gong Y**, Pepine CJ, Johnson JA, and Cooper-DeHoff RM. Lack of association of the *HMGA1* IVS5-13insC variant with type 2 diabetes in an ethnically diverse hypertensive case control cohort. *J Transl Med.* 2013. Jan 9;11(1):12. PMID: 23302499
116. Guo Y, Lanktree MB, Taylor KC, Hakonsarson H, Lange LA, Keating BJ; The IBC 50K SNP array BMI Consortium. Gene-centric meta-analyses of 108 912 individuals confirm known body mass index loci and reveal three novel signals. *Hum Mol Genet.* 2013 Jan 1;22(1):184-201. PMID: 23001569.

117. **Gong Y**, McDonough CW, Wang Z, Cooper-DeHoff RM, Langae TY, Beitelshes AL, Chapman AB, Gums JG, Bailey KR, Boerwinkle E, Turner ST, Johnson JA. Hypertension susceptibility loci and blood pressure response to antihypertensives – results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. *Circ Cardiovasc Genet*, 2012 Dec 1;5(6):686-91. PMID: 23087401
118. Asselbergs FW, Guo Y, van Iperen EPA, Sivapalaratnam S, Tragante V, Lanktree MB, Lange LA, Almoguera Castillo B, Appelman YE, Barnard J, Baumert J, Beitelshes AL, Bhangale TR, Ida Chen YD, Gaunt TR, **Gong Y**, Hopewell JC, Johnson T, Kleber ME, Langae TY, Li M, Li YR, Liu K, McDonough CW, Meijs MFL, Middelberg RPS, Musunuru K, Nelson CP, O'Connell JR, Padmanabhan S, Pankow JS, Pankratz N, Rafelt S, Rajagopalan R, Romaine SPR, Schork NJ, Shaffer J, Shen H, Smith EN, Tischfield SE, van der Most PJ, van Vliet-Ostaptchouk JV, Verweij N, Volcik KA, Zhang L, Bailey KR, Bailey KM, Bauer F, Boer JMA, Braund PS, Burt A, Burton PR, Buxbaum SG, Chen W, Cooper-DeHoff RM, Cupples LA, deJong JS, Delles C, Duggan D, Fornage M, Furlong CE, Glazer N, Gums JG, Hastie C, Holmes MV, Illig T, Kirkland SA, Kivimaki M, Klein R, Klein BE, Kooperberg C, Kottke-Marchant K, Kumari M, LaCroix AZ, Mallela L, Murugesan G, Ordovas J, Ouwehand WH, Post W, Saxena R, Scharnagl H, Schreiner PJ, Shah T, Shields DC, Shimbo D, Srinivasan SR, Stolk RP, Swerdlow DI, Taylor Jr. HA, Topol EJ, Toskala E, van Pelt JL, van Setten J, Yusuf S, Whittaker JC, Zwinderman AH, LifeLines Cohort Study, Anand SS, Balmforth AJ, Berenson GS, Bezzina CR, Boehm BO, Boerwinkle E, Casas JP, Caulfield MJ, Clarke R, Connell JM, Cruickshanks KJ, DavidsonKW, Day INM, de Bakker PIW, Doevendans PA, Dominiczak AF, Hall AS, Hartman CA, Hengstenberg C, Hillege HL, Hofker MH, Humphries SE, Jarvik GP, Johnson JA, Kaess BM, Kathiresan S, Koenig W, Lawlor DA, März W, Melander O, Mitchell BD, Montgomery GW, Munroe PB, Murray SS, Newhouse SJ, Onland-Moret NC, Poulter N, Psaty B, Redline S, Rich SS, Rotter JI, Schunkert H, Sever P, Shuldiner AR, Silverstein RL, Stanton A, Thorand B, Trip MD, Tsai MY, van der Harst P, Van Der Schoot E, van der Schouw YT, Monique Verschuren WM, Watkins H, Wilde AAM, Wolffenbuttel BHR, Whitfield JB, Hovingh HK, Ballantyne CM, Wijmenga C, Reilly MP, Martin NG, Wilson JG, Rader DJ, Samani NJ, Reiner AP, Hegele RA, Kastelein JJP, Hingorani AD, Talmud PJ, Hakonarson H, Elbers HC, Keating BJ, Drenos F. Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. *Am J Hum Genet*. 2012 Nov 2;91(5):823-38. PMID: 23063622
119. Vandell AG, Lobbmeyer MT, Gawronski BT, Langae TY, **Gong Y**, Gums JG, Beitelshes AL, Turner ST, Chapman AB, Cooper-DeHoff RM, Bailey KR, Boerwinkle E, Pepine CJ, Liggett SB, Johnson JA. G protein receptor kinase 4 (GRK4) polymorphisms: beta-blocker Pharmacogenetics and treatment related outcomes in hypertension. *Hypertension*, 2012;60(4):957-64. PMID: 22949529
120. Karnes JH, McDonough CW, **Gong Y**, Vo TT, Langae RY, Chapman AB, Gums JG, Beitelshes AL, Bailey KR, Del-Aquila JL, Boerwinkle E, Pepine CJ, Turner ST, Johnson JA, Cooper-DeHoff RM. Association of *KCNJ1* Variation with Change in Fasting Glucose

and New Onset Diabetes during HCTZ Treatment. *Pharmacogenomics J.* 2013;13(5):430-436. PMID: 22907731

121. Shafiu M, Johnson RJ, Turner ST, Langaee T, **Gong Y**, Chapman AB, Gums JG, Johnson JA. Urate transporter gene *SLC22A12* polymorphisms associated with obesity and metabolic syndrome in Caucasians with Hypertension. *Kidney Blood Press Res.* 2012 Jun 8;35(6):477-482. PMID: 22688828.
122. Wang D, Sun X, **Gong Y**, Gawronksi B, Langaee TY, Shahin MH, Khalifia SI, Johnson JA. *CYP2C9* promoter variable number tandem repeat polymorphism (pVNTR) regulates mRNA expression in human livers. *Drug Metab Dispos.* 2012 May;40(5):884-91. PMID: 22289258.
123. Duarte JD, Zineh I, Burkley B, **Gong Y**, Langaee TY, Turner ST, Chapman AB, Boerwinkle E, Gums JG, Cooper-DeHoff RM, Beitelshes AL, Bailey KR, Fillingim RB, Kone BC, Johnson JA. Effect of Genetic Variation in *H3K79* Methylation Regulatory Genes on Clinical Blood Pressure and Blood Pressure Response to Hydrochlorothiazide. *J Transl Med.* 2012 Mar 22;10:56. PMID: 22440088
124. Papp AC, Pinsonneault JK, Wang D, Peters B, Klungel O, **Gong Y**, Maitland-van der Zee A, Johnson JA, Kumari M, Hingorani AD, Talmud PJ, Shah S, Humphrieseys SE, Sadee W. Cholesterol Ester Transfer Protein (*CETP*) Polymorphism affects mRNA Splicing, HDL levels and sex-dependent cardiovascular risk, *PLoS One.* 2012;7(3):e31930. Epub 2012 Mar 5. PMID: 22403620
125. Smith SM, **Gong Y**, Turner ST, Cooper-DeHoff RM, Beitelshes AL, Chapman AB, Bailey K, Boerwinkle E, Johnson JA, Gums JG. Blood Pressure Responses and Metabolic Effects of Hydrochlorothiazide and Atenolol. *Am J Hypertens.* 2012 Mar;25(3):359-65. PMID: 22089105
126. Duarte JD, Turner ST, Tran B, Chapman AB, Bailey KR, **Gong Y**, Gums JG, Langaee TY, Beitelshes AL, Cooper-DeHoff RM, Boerwinkle E, Johnson JA. Association of Chromosome 12 locus with antihypertensive response to hydrochlorothiazide may involve differential *YEATS4* expression. *Pharmacogenomics Journal*, 2012, Feb 21. [Epub ahead of print] PMID: 22350108.
127. Sibille K, Langaee TY, Burkley B, **Gong Y**, Glover TL, King C, Riley J, Leeuwenburgh C, Staud R, Bradley LA, Fillingim RB. Chronic pain, perceived stress, and cellular aging: An exploratory study. *Molecular Pain*, 2012 Feb 12;8(1):12 [Epub ahead of print] PMID: 22325162
128. Saxena R, Elbers CC, Guo Y, Peter I, Gaunt TR, Mega JL, Lanktree MB, Tare A, Castillo BA, Li YR, Johnson T, Bruinenberg M, Gilbert-Diamond D, Rajagopalan R, Voight BF, Balasubramanyam A, Barnard J, Bauer F, Baumert J, Bhangale T, Böhm BO, Braund PS, Burton PR, Chandrupatla HR, Clarke R, Cooper-Dehoff RM, Crook ED, Davey-Smith G, Day IN, de Boer A, de Groot MC, Drenos F, Ferguson J, Fox CS, Furlong CE, Gibson Q,

- Gieger C, Gilhuijs-Pederson LA, Glessner JT, Goel A, **Gong Y**, Grant SF, Grobbee DE, Hastie C, Humphries SE, Kim CE, Kivimaki M, Kleber M, Meisinger C, Kumari M, Langaee TY, Lawlor DA, Li M, Lobbmeyer MT, Maitland-van der Zee AH, Meijis MF, Molony CM, Morrow DA, Murugesan G, Musani SK, Nelson CP, Newhouse SJ, O'Connell JR, Padmanabhan S, Palmen J, Patel SR, Pepine CJ, Pettinger M, Price TS, Rafelt S, Ranchalis J, Rasheed A, Rosenthal E, Ruczinski I, Shah S, Shen H, Silbernagel G, Smith EN, Spijkerman AW, Stanton A, Steffes MW, Thorand B, Trip M, van der Harst P, van der A DL, van Iperen EP, van Setten J, van Vliet-Ostaptchouk JV, Verweij N, Wolffenbuttel BH, Young T, Zafarmand MH, Zmuda JM; the Look AHEAD Research Group; DIAGRAM consortium, Boehnke M, Altshuler D, McCarthy M, Kao WH, Pankow JS, Cappola TP, Caulfield M, Dominiczak A, Shields DC, Bhatt D, Zhang L, Curtis SP, Danesh J, Casas JP, van der Schouw YT, Onland-Moret NC, Doevendans PA, Dorn GW 2nd, Farrall M, Fitzgerald GA, Hamsten A, Hegele R, Hingorani AD, Hofker MH, Huggins GS, Illig T, Jarvik GP, Johnson JA, Klungel OH, Knowler WC, Koenig W, März W, Meigs JB, Melander O, Munroe PB, Mitchell BD, Bielinski SJ, Rader DJ, Reilly MP, Rich SS, Rotter JI, Saleheen D, Samani NJ, Schadt EE, Shuldiner AR, Silverstein R, Kottke-Marchant K, Talmud PJ, Watkins H, Asselbergs F, de Bakker PI, McCaffery J, Wijmenga C, Sabatine MS, Wilson JG, Reiner A, Bowden DW, Hakonarson H, Siscovick DS, Keating BJ. Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. *Am J Hum Genet*. 2012 Apr 6;90(4):753. Feb 8. [Epub ahead of print] PMID: 22325160
129. Bavry AA, Khaliq A, **Gong Y**, Handberg EM, Cooper-DeHoff RM, Pepine CJ. Harmful effects of Nonsteroidal Anti-Inflammatory Drugs among Patients with Hypertension and Coronary Artery Disease. *Am J Med*. 2011; 124(7):614-20. PMID: 21596367
130. Shroads AL, Langaee TY, Coats BS, Kurtz TL, Bullock JR, Weithorn D, **Gong Y**, Wagner DA, Ostrov DA, Johnson JA, Stacpoole PW. Human Polymorphisms in the Glutathione Transferase Zeta 1/Maleylacetoacetate Isomerase Gene Influence the Toxicokinetics of Dichloroacetate, *J Clin Pharmacol*. 2012 Jun;52(6):837-49. PMID: 21642471
131. Katz J*, **Gong Y***, Salmasinia D, Hou W, Burkley B, Ferreira P, Casanova O, Langaee TY, Moreb JS. Genetic Polymorphisms and Other Risk Factors Associated with Bisphosphonate Induced Osteonecrosis of the Jaw (BONJ). *Int J Oral Maxillofac Surg*, 2011; 40 (6): 605–611. PMID: 21396799 *first authors
132. **Gong Y**, Beitelshees AL, Cooper-DeHoff RM, Lobbmeyer MT, Langaee TY, Wu J, Cresci S, Province MA, Spertus JA, Pepine CJ, Johnson JA. Chromosome 9p21 Haplotypes and Prognosis in White and Black Patients with Coronary Artery Disease. *Circ Cardiovasc Genet*. 2011; 4:169-178. PMID: 21372283
133. Shahin MH, Khalifa SI, **Gong Y**, Sallam TH, Hammad LN, Shafey ME, Ali SS, Mohamed MEF, Langaee T, Johnson JA. Genetic and Nongenetic Factors Associated with Warfarin Dose Requirements in Egyptian Patients. *Pharmacogenetics and Genomics*, 2011;21(3):130–135. PMID: 21228733

134. Lanktree MB, Guo Y, Murtaza M, Glessner JT, Bailey SD, Onland-Moret NC, Lettre G, Ongen H, Rajagopalan R, Johnson T, Shen H, Nelson CP, Klopp N, Baumert J, Padmanabhan S, Pankratz N, Pankow JS, Shah S, Taylor K, Barnard J, Peters BJ, M Maloney C, Lobbmeyer MT, Stanton A, Zafarmand MH, Romaine SP, Mehta A, van Iperen EP, **Gong Y**, Price TS, Smith EN, Kim CE, Li YR, Asselbergs FW, Atwood LD, Bailey KM, Bhatt D, Bauer F, Behr ER, Bhangale T, Boer JM, Boehm BO, Bradfield JP, Brown M, Braund PS, Burton PR, Carty C, Chandrupatla HR, Chen W, Connell J, Dalgeorgou C, Boer AD, Drenos F, Elbers CC, Fang JC, Fox CS, Frackelton EC, Fuchs B, Furlong CE, Gibson Q, Gieger C, Goel A, Grobbee DE, Hastie C, Howard PJ, Huang GH, Johnson WC, Li Q, Kleber ME, Klein BE, Klein R, Kooperberg C, Ky B, Lacroix A, Lanken P, Lathrop M, Li M, Marshall V, Melander O, Mentch FD, J Meyer N, Monda KL, Montpetit A, Murugesan G, Nakayama K, Nondahl D, Onipinla A, Rafelt S, Newhouse SJ, Otieno FG, Patel SR, Putt ME, Rodriguez S, Safa RN, Sawyer DB, Schreiner PJ, Simpson C, Sivapalaratnam S, Srinivasan SR, Suver C, Swergold G, Sweitzer NK, Thomas KA, Thorand B, Timpson NJ, Tischfield S, Tobin M, Tomaszewski M, Verschuren WM, Wallace C, Winkelmann B, Zhang H, Zheng D, Zhang L, Zmuda JM, Clarke R, Balmforth AJ, Danesh J, Day IN, Schork NJ, de Bakker PI, Delles C, Duggan D, Hingorani AD, Hirschhorn JN, Hofker MH, Humphries SE, Kivimaki M, Lawlor DA, Kottke-Marchant K, Mega JL, Mitchell BD, Morrow DA, Palmen J, Redline S, Shields DC, Shuldiner AR, Sleiman PM, Smith GD, Farrall M, Jamshidi Y, Christiani DC, Casas JP, Hall AS, Doevendans PA, D Christie J, Berenson GS, Murray SS, Illig T, Dorn GW 2nd, Cappola TP, Boerwinkle E, Sever P, Rader DJ, Reilly MP, Caulfield M, Talmud PJ, Topol E, Engert JC, Wang K, Dominiczak A, Hamsten A, Curtis SP, Silverstein RL, Lange LA, Sabatine MS, Trip M, Saleheen D, Peden JF, Cruickshanks KJ, März W, O'Connell JR, Klungel OH, Wijmenga C, Maitland-van der Zee AH, Schadt EE, Johnson JA, Jarvik GP, Papanicolaou GJ; Hugh Watkins on behalf of PROCARDIS, Grant SF, Munroe PB, North KE, Samani NJ, Koenig W, Gaunt TR, Anand SS, van der Schouw YT; Meena Kumari on behalf of the Whitehall II Study the WHII 50K Group, Soranzo N, Fitzgerald GA, Reiner A, Hegele RA, Hakonarson H, Keating BJ. Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height. *Am J Hum Genet*, 2011;88(1):6-18 PMID: 21194676
135. Beitelshes AL, Johnson JA, Hames M, **Gong Y**, Cooper-DeHoff RM, Wu Ju, Cresci S, Ma CX, Pepine CJ, Province MA, Spertus JA, McLeod HL. Aromatase Gene Polymorphism are Associated with Survival among Patients with Cardiovascular Disease in a Sex-dependent Manner. *PLoS ONE* 2010;5(12): e15180 PMID: 21170323
136. Niu Y*, **Gong Y***, Langae TY, Davis H, Elewa H, Beitelshes AL, Moss JI, Cooper-Dehoff RM, Pepine CJ, Johnson JA. Genetic Variation in the Beta 2 Subunit of the Voltage-Gated Calcium Channel (*CACNB2*) and Pharmacogenetic Association with Adverse Cardiovascular Outcomes in the International Verapamil SR- Trandolapril Study-Genetic Substudy (INVEST-GENES) *Circ Cardiovasc Genet*, 2010;3:548-555 PMID: 21156931
*first authors.
137. Denardo SJ, **Gong Y**, Nichols WW, Messerli FH, Cooper-DeHoff RM, Handberg EM, Champion A, Pepine CJ. Blood Pressure and Outcomes in Very Old Hypertensive

Coronary Artery Disease Patients: An International Verapamil SR-Trandolapril Study (INVEST) Substudy, *American Journal of Medicine* 2010;123:719-726 PMID: 20670726

138. Denardo SJ, Messerli FH, Gaxiola E, Aranda JM, Cooper-DeHoff RM, Handberg EM, **Gong Y**, Champion A, Zhao Q, Pepine CJ. Coronary Revascularization Strategy and Outcomes According to Blood Pressure: An International Verapamil SR-Trandolapril Study (INVEST) Substudy. *Am J Cardiol* 2010;106:498-503 PMID: 20691307
139. Cooper-DeHoff RM, **Gong Y**, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, Pepine CJ. Tight Blood Pressure Control and Cardiovascular Outcomes among Hypertensive Patients with Diabetes and Coronary Artery Disease. *JAMA* 2010;304:61-68 PMID: 20606150
140. Cooper-DeHoff RM, Wen S, Beitelshes AL, Zineh I, Gums JG, Turner ST, **Gong Y**, Hall K, Parekh V, Chapman A, Boerwinkle E, Johnson JA. Impact of Abdominal Obesity on Incidence of Adverse Metabolic Effects Associated with Antihypertensive Medications. *Hypertension* 2010;55:61-68 PMID: 19917874
141. Bavry AA, Anderson RD, **Gong Y**, Denardo SJ, Cooper-DeHoff RM, Handberg EM, Pepine CJ. Prognosis and Treatment Considerations of Concomitant Peripheral Arterial and Coronary Artery Disease: Findings from the INVEST Trial. *Hypertension* 2010;55:48-53 PMID: 19996066
142. Beitelshes AL, **Gong Y**, Bailey KR, Turner ST, Chapman AB, Schwartz GL, Gums JG, Boerwinkle E, Johnson JA. Comparison of Office, Ambulatory, and Home Blood Pressure Antihypertensive Response to Atenolol and Hydrochlorothiazide. *J Clin Hypertens* 2010 Jan;12(1):14-21 PMID: 20047624
143. Smith SM, Anderson SD, Wen S, **Gong Y**, Turner ST, Cooper-DeHoff RM, Schwartz GL, Bailey K, Chapman A, Hall KL, Feng H, Boerwinkle E, Johnson JA, Gums JG. Thiazide-Induced Hyperglycemia is not Related to Hypokalemia: Results from the Pharmacogenomic Evaluation of Antihypertensive Response (PEAR) Study. *Pharmacotherapy* 2009 Oct;29(10):1157-65 PMID: 19792989
144. **Gong Y**, Handberg EM, Cooper-DeHoff RM, Matyas K, Johnson JA, Pepine CJ, for the INVEST investigators. Systolic Blood Pressure and Subjective Well-being in Patients with Coronary Artery Disease. *Clin Cardiol* 2009 Nov;32(11):627-32 PMID: 19711440
145. Beitelshes AL, Navare H, Wang D, **Gong Y**, Wessel J, Moss JI, Langae TY, Cooper DeHoff RM, Sadee W, Pepine CJ, Schork NJ, Johnson JA. *CACNA1C* Gene Polymorphisms, Cardiovascular Disease Outcomes and Treatment Response. *Circ Cardiovasc Genet* 2009 Aug;2(4):362-70 PMID: 20031608.
146. Johnson JA, **Gong Y**, Bailey KR, Cooper-DeHoff RM, Chapman AB, Turner ST, Schwartz GL, Campbell K, Schmidt S, Beitelshes AL, Boerwinkle E, Gums JG.

Combination Antihypertensive Therapy with Hydrochlorothiazide and Atenolol: Effect of Initiation Order. *Clin Pharmacol Ther* 2009 Nov;86(5):533-9 PMID: 19571804

147. Johnson JA, Boerwinkle E, Zineh I, Chapman AB, Bailey KR, Cooper-DeHoff RM, Gums JG, Curry RW, **Gong Y**, Beitelshes AL, Schwartz GL, Turner ST. Pharmacogenomics of Antihypertensive Drugs: Rationale and Design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study. *Am Heart J* 2009 Mar;157(3):442-9 PMID: 19249413
148. Denardo SJ, Messerli FH, Gaxiola E, Aranda JM, Cooper-DeHoff RM, Handberg EM, **Gong Y**, Champion A, Zhou Q, Pepine CJ. Characteristics and Outcomes of Revascularized Patients with Hypertension: A Substudy of the International Verapamil SR-Trandolapril Study, *Hypertension* 2009 Apr;53(4):624-30 PMID: 19237684
149. Johnson AD, **Gong Y**, Wang D, Langaee TY, Shin J, Cooper-DeHoff RM, Schork NJ, Binkley P, Pepine CJ, Johnson JA, Sadee W. Promoter Polymorphisms in ACE (Angiotension-I Converting Enzyme) Associated with Clinical Outcomes in Hypertension. *Clin Pharmacol Ther* 2009 Jan;85(1):36-44 PMID: 18946466
150. Pacanowski MA, **Gong Y**, Cooper-DeHoff RM, Schork NJ, Shriver MD, Langaee TY, Pepine CJ, Johnson JA. β -adrenergic Receptor Gene Polymorphisms and β -blocker Treatment Outcomes in Hypertension, *Clin Pharmacol Ther* 2008 Dec;84(6):715-21 PMID: 18615004
151. Gerhard T, **Gong Y**, Beitelshes AL, Lobmeyer MT, Cooper-DeHoff RM, Langaee TY, Schork NJ, Pepine CJ, Johnson JA, for the INVEST Investigators. Association between Cardiovascular Outcomes, Diuretic Therapy and the α -adducin Polymorphism: Results from the International Verapamil SR-Trandolapril Study GENETic Substudy (INVEST-GENES). *Am Heart J*, 2008 Aug;156 (2):397-404 PMID: 18657677
152. Hassan M, York KM, Li H, Li Q, **Gong Y**, Langaee TY, Fillingim RB, Johnson JA, Sheps DS. Association of Beta1-Adrenergic Receptor Genetic Polymorphism with Mental Stress-induced Myocardial Ischemia in Patients with Coronary Artery Disease. *Arch Intern Med* 2008 Apr;168(7):763-70 PMID: 18413560
153. Shin J, Kline S, Moore M, **Gong Y**, Bhanderi V, Schmalfluss CM, Johnson JA, Schofield RS. Association of Diurnal Blood Pressure Pattern with Risk of Hospitalization or Death in Men with Heart Failure. *J Card Fail* 2007;13:656-62 PMID: 17923358
154. Beitelshes AL, **Gong Y**, Wang D, Schork NJ, Cooper-DeHoff RM, Langaee TY, Shriver MD, Sadee W, Knot HJ, Pepine CJ, Johnson JA. *KCNMB1* Genotype Influences Response to Verapamil SR and Adverse Outcomes in the International Verapamil SR/Trandolapril Study (INVEST). *Pharmacogenet Genomics* 2007 Sep;17(9):719-729 PMID: 17700361
155. Brunner M, Cooper-Dehoff RM, **Gong Y**, Karnes JH, Langaee TY, Pepine CJ, Johnson JA. Factors Influencing Blood Pressure Response to Trandolapril Add-on therapy in

Patients Taking Verapamil SR (from the International Verapamil SR Trandolapril Study (INVEST)). *Am J Cardiol* 2007;99:1549-1554 PMID: 17531579

156. Langaee TY, **Gong Y**, Yarandi HN, Katz DA, Cooper-DeHoff RM, Pepine CJ, Johnson JA. Association of CYP3A5 Polymorphisms with Hypertension and Antihypertensive Response to Verapamil. *Clin Pharmacol Ther* 2007;81:386-391 PMID: 17339868
157. Lobmeyer MT, **Gong Y**, Terra SG, Beitelshes AL, Langaee TY, Pauly DF, Schofield RS, Hamilton KK, Patterson HJ, Adams KF, Hill JA, Aranda JM, Johnson JA. Synergistic Polymorphisms of Beta1 and Alpha2c-Adrenergic Receptors and the Influence on Left Ventricular Ejection Fraction Response to Beta-blocker Therapy in Heart Failure. *Pharmacogenet Genomics* 2007;17:277-282 PMID: 17496726
158. Shin J, Lobmeyer MT, **Gong Y**, Zineh I, Langaee TY, Yarandi H, Schofield RS, Aranda JM, Hill JA, Pauly DF, Johnson JA. Relation of Beta (2)-adrenoceptor Haplotype to Risk of Death and Heart Transplantation in Patients with Heart Failure. *Am J Cardiol* 2007;99:250-255 PMID: 17223428
159. **Gong Y**, Beitelshes AL, Wessel J, Langaee TY, Schork NJ, Johnson JA. Single Nucleotide Polymorphism Discovery and Haplotype Analysis of Ca²⁺-dependent K⁺ Channel Beta-1 Subunit. *Pharmacogenet Genomics* 2007;17:267-275 PMID: 17496725
160. **Gong Y**, Meyer EM, Meyers CA, Klein RL, King MA, Hughes JA. Memory-related Deficits Following Selective Hippocampal Expression of Swedish Mutation Amyloid Precursor Protein in the Rat. *Exp Neurol* 2006; 200:371-377 PMID: 16780838
161. Zuo J, Jian J, Chen SH, Vergara S, **Gong Y**, Xue J, Huang H, Kaku M, Holliday LS. Actin Binding Activity of Subunit B of Vacuolar H⁺-ATPase is Involved in its Targeting to Ruffled Membranes of Osteoclasts. *J Bone Miner Res* 2006;21 (5):714-21 PMID: 16734386
162. **Gong Y**, Wang Z, Liu T, Zhao W, Zhu Y, Johnson JA, Wu R. A Statistical Model for Functional Mapping of Quantitative Trait Loci Regulating Drug Response. *Pharmacogenomics J* 2004;4:315-321 PMID: 15263889
163. **Gong Y**, Chen SZ, Sonntag CF, Sumners C, Klein RL, King MA, Hughes JA, Meyer EM. Recombinant Adeno-associated Virus Serotype 2 Effectively Transduces Primary Rat Brain Astrocytes and Microglia. *Brain Research Protocols* 2004;14:18-24 PMID: 15519948
164. Klein RL, Hamby ME, **Gong Y**, Hirko AC, Wang S, Hughes JA, King MA, Meyer EM. Dose and Promoter Effects of Adeno-associated Viral Vector for Green Fluorescent Protein Expression in the Rat Brain. *Exp Neurol* 2002;176:66-74 PMID: 12093083

LETTERS TO THE EDITOR:

1. **Gong Y**, Beitelshes AL, Cooper-DeHoff RM, Lobmeyer MT, Langaee TY, Wu J, Cresci S, Province MA, Spertus JA, Pepine CJ, Johnson JA. Response to Letter Regarding Article

"Chromosome 9p21 Haplotypes and Prognosis in white and Black Patients with Coronary Artery Disease". *Circ Cardiovasc Genet*. 2011;4 (4): e12. PMID: 21846865

2. Cooper-DeHoff RM, **Gong Y**, Pepine CJ. Hypertension Control and Cardiovascular Outcomes among Patients with Diabetes and Coronary Artery Disease Reply. *JAMA* 2010;304:1672-1673

PUBLISHED ABSTRACTS:

1. Tantawy M, Chekka LM, Garrett TJ, Singh S, Shah CP, Fradley MG, Cornel RF, Baz R, DeRemer DL, Yuan L, Langaee T, March K, Pepine CJ, Moreb JS, **Gong Y**. Lactate Dehydrogenase B and pyruvate oxidation associated with carfilzomib-related cardiotoxicity in multiple myeloma patients: a multi-omics study. *Circulation*. 2020. To be presented as a virtual poster at the American Heart Association's Scientific Sessions 2020 November 13-17.
2. Fradley MG, Nguyen NK, Chen Y, Guha A, Upshaw J, Ky B, **Gong Y**. Cardiovascular Toxicities of Cyclin Dependent Kinase (CDK) 4/6 inhibitors in Metastatic Breast Cancer Patients. *Circulation*. 2020. To be presented as a virtual moderated poster at the American Heart Association's Scientific Sessions 2020 November 13-17.
3. Nguyen NK, Fradley MG, Chen Y, DeRemer D, Waheed N, Langaee T, Ahamd F, Cooper-DeHoff RM, Pepine CJ, **Gong Y**. Racial/ethnic differences in cardiac surveillance evaluation for cancer patients treated with anthracycline-based chemotherapy: the OneFlorida Clinical Research Consortium. *Circulation*. 2020. To be presented as an oral presentation at the American Heart Association's Scientific Sessions 2020 November 13-17.
4. Stolte S, Wu Y, Hogan WR, **Gong Y**, Fang R. Artificial intelligence for characterizing heart failure in cardiac magnetic resonance images. *Circulation*. 2020. To be presented as a virtual poster at the American Heart Association's Scientific Sessions 2020 November 13-17.
5. Yang G, Singh S, McDonough CW, Van Driest S.L, Hamadeh IS, Katz J, Lakatos P, Balla B, Kosa JP, Pelliccioni GA, Price D, Figg WD, Langaee TY, Moreb JS, **Gong Y**. *FDFT1* Locus associated with bisphosphonate-related osteonecrosis of the jaw: an international genome-wide meta-analysis. To be presented as a virtual poster at the American Society of Human Genetics 2020 Annual Meeting, October 27-30, 2020.
6. Stolte SE, Wu Y, **Gong Y**, Fang R. Heart failure classification and prediction from cardiac magnetic resonance imaging using machine learning. Submitted to the 106th Radiological Society of North America Annual meeting in Chicago, IL. Nov 29-Dec 4, 2020.
7. Tantawy M, Chekka LM, Langaee TY, Garrett T, Fradley MG, Cornell RF, Baz RC, Singh S, Yuan L, Shah CP, Waheed N, Pepine CJ, Moreb JS, **Gong Y**. Differential expressions of miR-17 and complement factor D in carfilzomib-related cardiotoxicity in multiple myeloma patients: results of microRNA array and proteomics integrated analysis. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-

28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 3694.

8. Pruitt EY, Guang Y, Chen Y, Upchurch GR, Johnson JA, **Gong Y**. *ADAMTS8* locus associated with abdominal aortic aneurysms in the UK biobank. *Arterioscler Thromb Vasc Biol.* 2020;40:A379. ePoster presented at the Vascular Discovery: From Genes to Medicine 2020 Scientific Sessions; May 5-7, 2020. Published on line on June 29, 2020 at: https://www.ahajournals.org/doi/10.1161/atvb.40.suppl_1.379
9. Lee CR, Beitelshes AL, Tuteja S, Angiolillo DJ, Limdi NA, Empey PE, Lee JC, Johnson JA, Duarte JD, Skaar TC, Cheng Y, **Gong Y**, McDonough CW, Dillon C, Franchi F, Kruetz RP, Stouffer GA, Cavallari LH. Impact of the CYP2C19 *17 allele on cardiovascular outcomes following implementation of genotype-guided antiplatelet therapy in a real-world setting. *Clin Pharmacol Ther.* 2020,107 (S1): Abstract at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2020 Annual Meeting; March 18-21, 2020; Houston TX.
10. Thomas CD, Elsey AR, Starostik P, **Gong Y**, Deen JT, Pulido LF, Prieto H, Fillingim R, Gray CF, Parvataneni HK, Johnson JA, Cavallari LH. Precise Pain Control: Feasibility and Efficacy of a Preemptive CYP2D6-genotype Guided Post-operative Pain Management Paradigm. *Clin Pharmacol Ther.* 2020,107 (S1): S25: PT-013. Abstract presented at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2020 Annual Meeting (Presidential Trainee Award); March 18-19, 2020; Houston TX.
11. Mosley SA, El Roubay N, Kim S, Lingineni K, **Gong Y**, Estores, D, Feng K, Kim H, Kinjo M, Langae T, Li Z, Schmidt S, Johnson JA, Frye R, Binkley P, Schmidt S, Cavallari LH. Randomized, Prospective, Clinical trial comparing extended-release (ER) formulations: Metoprolol Succinate Case study. *Clin Pharmacol Ther.* 2020,107 (S1): S99-S100, PIII-080. Abstract presented at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2020 Annual Meeting; March 18-19, 2020; Houston TX.
12. Tantawy M, Singh S, Yang G, Gitzendanner M, Chen Y, Wu Y, Fang R, Hogan WR, **Gong Y**. ZMAT4 and DOCK9 variants associated with heart failure in breast cancer patients in the UK Biobank data. *Clin Pharmacol Ther.* 2020,107 (S1): S26, PT-017. Abstract presented at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2020 Annual Meeting (Presidential Trainee-David J Goldstein Trainee Award, Top trainee abstract); March 18-19, 2020; Houston TX.
13. Singh S, Yang G, Gitzendanner M, Chen Y, Tantawy M, Wu Y, Fang R, Hogan WR, **Gong Y**. Phospholipase D Pathway Implicated in Heart Failure in Cancer Patients: Results from the UK Biobank. *Clin Pharmacol Ther.* 2020,107 (S1): S84, PIII-020. Abstract presented at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2020 Annual Meeting; March 19, 2020; Houston TX.
14. Yang G, Singh S, Chen Y, **Gong Y**. Phenome-wide Association studies (PheWAS) of *SIRT1* SNP in UK Biobank. *Clin Pharmacol Ther.* 2020,107 (S1):S116, PIII-137. Abstract presented at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2020 Annual Meeting; March 19, 2020; Houston TX.

15. Yang G, Singh S, Collins JM, Langaee TY, McDonough CW, Holliday LS, Wang D, Lamba J, **Gong Y**. *SIRT1* functional SNPs associated with bisphosphonate-related osteonecrosis of the Jaw. *Clin Pharmacol Ther*. 2020;107 (S1): S89, PIII-038. Abstract presented at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2020 Annual Meeting; March 19, 2020; Houston TX.
16. Huang Y, Garrett TJ, Yuan L, Fradley MG, Cornell RF, Baz RC, Shah CP, Langaee TY, Waheed N, March K, Pepine CJ, Moreb JS, **Gong Y**. Global metabolomic profiling reveals lower lysophospholipid levels in multiple myeloma patients with carfilzomib-related cardiotoxicity. *Circulation*. 2019;140:A9892. Presented as a poster at the American Heart Association's Scientific Sessions 2019 (AHA Genomic and Precision Medicine Travel Grant Winner) in Philadelphia, PA on November 18, 2019.
17. Langaee TY, Asher M, **Gong Y**, Lima ET, Antwi S, Enimil A, Dompok A, Yang H, Alghamdi WA, Wiesner L, Peloquin CA, Kwara A. Predicting nevirapine concentrations using pharmacogenetics in Ghanaian HIV-infected children (Abstract/Program #499). Poster presented at the American Society of Human Genetics (ASHG) 2019 Annual Meeting, Oct 17, 2019 in Houston TX.
18. Yang G, Singh S, Langaee TY, Lamba J, **Gong Y**. *SIRT1* Promoter SNP associated with bisphosphonate-related osteonecrosis of the Jaw. Poster presented at American Society of Bone and Mineral Research (ASBMR) 2019 Annual Meeting (Young Investigator Award), Sep 22, 2019 in Orlando FL.
19. Mehanna M, Chen YE, **Gong Y**, Handberg EM, Roth B, De Leon J, Smith SM, Paulson H, Montilla-Crespo J, Harrell JG, Cooper-DeHoff RM. Optimizing Precision of Hypertension Care to Maximize Blood Pressure Control (OPTI-BP): A Pilot Study Utilizing a Smartphone App. *Hypertension* 2019;74(Suppl.1):AP181. Poster presentation at the AHA Annual Meeting. September 5-8, 2019. New Orleans, LA.
20. Waheed N, Mahmoud A, Shah C, Yonghui Wu, March K, Pepine CJ, **Gong Y**. Global longitudinal strain among patients with immune checkpoint inhibitor-induced cardiotoxicity: a case series. *JACC. March 2019 73 (9 S1):1595*; DOI: 10.1016/S0735-1097(19)32201-6 Presented as a poster at the American College of Cardiology's 68th Annual Scientific Session. March 17, 2019 in New Orleans, LA.
21. Thomas CD, Mosley SA, El Roubay N, Kim S, Lingineni K, Langaee T, **Gong Y**, Johnson JA, Schmidt SO, Schmidt S, Frye RF, Cavallari LH. Determination of CYP2D6 Phenotyping for Metoprolol using the *CYP2D6* Genotype-derived Activity Score: Results from a Prospective, Clinical Trial. *Clinical Pharmacology & Therapeutics* 2019, 105 (S1):S40: LB-028. Abstract presented at the American Society for Clinical Pharmacology and Therapeutics 2019 Annual Meeting; March 13, 2019; Washington DC.
22. Shahin MH, **Gong Y**, Singh S, Beitelshees AL, Chapman AB, Gums JG, Boerwinkle E, Turner ST, Cooper-DeHoff RM, Garrett T, Johnson JA. Machine learning uncovers novel biomarkers of antihypertensive response in the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. *Clinical Pharmacology & Therapeutics*. 2019; 105 (S1): S27: PT-013. Abstract presented at the American Society for Clinical Pharmacology and Therapeutics 2019 Annual Meeting (Presidential Trainee Winner); March 13, 2019; Washington DC.

23. Singh S, Warren HR, Hiltunen TP, Slavi E, El-Rouby N, Garofaltdou T, Fyhrust F, Kontula KK, Glorioso V, Zaninello R, Glorioso, Pepine CJ, Munroe PB, Beitelshes AL, Turner ST, Chapman AB, Boerwinkle E, Johnson JA, **Gong Y**, Cooper-DeHoff RM. Genome wide meta-analysis of blood pressure response to B-blockers: Results from International Consortium of Antihypertensive Pharmacogenomics Studies. *Clinical Pharmacology & Therapeutics* 2019, 105 (S1):S27: PT-014. Abstract presented at the American Society for Clinical Pharmacology and Therapeutics 2019 Annual Meeting (Presidential Trainee Winner); March 13, 2019; Washington DC.
24. Yang G, Singh S, McDonough CW, Hamadeh IS, Langae TY, Katz J, Lakatos P, Balla B, Kosa JP, Vaszilko M, Pelliccioni GA, Price D, Milshtein KG, Figg WD, Moreb JS, **Gong Y**. An international genome-wide meta-analysis of bisphosphonate related osteonecrosis of the jaw. *Clinical Pharmacology & Therapeutics* 2019, 105 (S1):S28: PT-016. Abstract presented at the American Society for Clinical Pharmacology and Therapeutics 2019 Annual Meeting (Presidential Trainee Winner); March 13, 2019; Washington DC.
25. Lima ET, **Gong Y**, Langae T, Antwi S, Enimil A, Dompheh A, Kwara A. The effect of CAR and PXR genetic variation (SNPs) on efavirenz pharmacokinetics in Ghanaian HIV+ and HIV/TB+ children. *Clinical Pharmacology & Therapeutics* 2019, 105 (S1):S104: PIII-078. Abstract presented at the American Society for Clinical Pharmacology and Therapeutics 2019 Annual Meeting; March 15, 2019; Washington DC.
26. Cooper-Dehoff RM, **Gong Y**, McAuliffe K, Bian J, Song W, Linton MF, Fonseca Price-Haywood, Guhl EN, King JB, Shaw R, PuroJ, Margolis K, Chamberlain A. PCSK9 Inhibitor Use in the Real World: Data from the National Patient Centered Research Network (PCORNet). *Circulation* 2018. Presented as a Late-breaking abstract at the American Heart Association's Scientific Sessions 2018. Chicago, IL. November 11, 2018.
27. Waheed N, Shah C, Boyd C. March K, Moreb JS, Yonghui Wu, **Gong Y**. Cardiotoxicity Associated with Immune Checkpoint Inhibitors: A single Center Experience. *Circulation*. 2018;138:A14262. Presented as a poster at the American Heart Association's Scientific Sessions 2018. Chicago, IL. November 11, 2018.
28. Shah C, Waheed N, Boyd C. March K, Yonghui Wu, **Gong Y**. Moreb JS. Cardiotoxicity due to Proteasome Inhibitors: More likely With Immunomodulators Or Anthracyclines. *Circulation*. 2018;138:A16441. Presented as a poster at the American Heart Association's Scientific Sessions 2018. Chicago, IL. November 11, 2018.
29. Shah C, Moreb JS, Kannampuzha J, Yaron J, Ambadapadi S, Yao J, Schultz-Cherry S, House M, Maranian P, Zhang L, **Gong Y**, Pepine CJ, Varsani A, Lucas A. Identification of Viral Gene Signatures in Cancer Patients with Reduced Ejection Fraction After Chemotherapy. *Circulation*. 2018;138:A15398. Presented as a poster at the American Heart Association's Scientific Sessions 2018. Chicago, IL. November 11, 2018.
30. Mosley S, Frye R, Langae T, Schmidt S.O.F., Schmidt S, **Gong Y**, Binkley P, Johnson JA, Cavallari LH. Determination of CYP2D6 phenotyping for metoprolol using the genotype-

derived activity score. Poster presentation for ACCP Updates in Therapeutics 2018 meeting (F-42). Jacksonville, FL. February 16-18, 2018.

31. Smith DM, Weitzel KW, Elsey AR, Wake DT, **Gong Y**, Duong BQ, Newsom K, Smith SM, Starostik P, Clare-Salzler MJ, Schmidt SO, Johnson JA, Fillingim R, Cavallari LH. Outpatient *CYP2D6* Genotype -Supported Opioid Therapy: A Prospective Trial. *Clinical Pharmacology & Therapeutics* 2018; 103: S1. (PT-012). Abstract presented at the American Society for Clinical Pharmacology and Therapeutics 2018 Annual Meeting; March 22, 2018; Orlando, FL.
32. Schwartz EJ, Mougey EB, Chambers NA, Denham JM, Al-Atrash H, Gomez RA, Palomo PJ, Taufiq S, George DE, Evans J, **Gong Y**, Blake KV, Johnson JA, Lima JJ, Franciosi JP. Novel Implementation of Genotype-Guided Proton Pump Inhibitor Therapy in Children: A Pilot, Randomized, Multi-Site Pragmatic Trial. *Clin Pharmacol Ther* 2018;103:S16 (LB-003). Abstract presented at the American Society for Clinical Pharmacology and Therapeutics 2018 Annual Meeting; March 22, 2018; Orlando, FL.
33. S. Singh, Z. Wang, M.H. Shahin, T.Y. Langaee, **Y. Gong**, C.W. McDonough, K.R. Bailey, S.T. Turner, A. Chapman, J.G. Gums, A.L. Beitelshes, R.M. Cooper-DeHoff, S. Scherer, E. Boerwinkle, J.A. Johnson. TARGETED SEQUENCING IDENTIFIES MISSENSE VARIANT IN THE BEST3 GENE ASSOCIATED WITH ANTIHYPERTENSIVE RESPONSE TO THIAZIDE DIURETICS (2018), American Society for Clinical Pharmacology and Therapeutics. *Clin. Pharmacol. Ther.*, 103: S5. doi:10.1002/cpt.993 (PT-001). Abstract presented at the American Society for Clinical Pharmacology and Therapeutics 2018 Annual Meeting; March 22, 2018; Orlando, FL.
34. S. Singh, **Y. Gong**, C.W. McDonough, K.R. Bailey, A.L. Beitelshes, E. Boerwinkle, A.B. Chapman, J.G. Gums, S.T. Turner, R.M. Cooper-DeHoff, J.A. Johnson. GENOME WIDE ASSOCIATION STUDY IDENTIFIES NOVEL PHARMACOGENETIC VARIANTS ASSOCIATED WITH CHLORTHALIDONE BLOOD PRESSURE RESPONSE IN AFRICAN AMERICANS (2018), American Society for Clinical Pharmacology and Therapeutics. *Clin. Pharmacol. Ther.*, 103: S50. doi:10.1002/cpt.993 (PI-139). Abstract presented at the American Society for Clinical Pharmacology and Therapeutics 2018 Annual Meeting; March 22, 2018; Orlando, FL.
35. Shahin MH, Conrado DJ, Gonzalez D, **Gong Y**, Lobmeyer MT, Beitelshes AL, Boerwinkle E, Gums JG, Chapman A, Turner ST, Cooper-DeHoff RM, Johnson JA. GENOME-WIDE META-ANALYSES REVEAL NOVEL PREDICTORS OF HEART RATE RESPONSE TO β -BLOCKERS IN THE PHARMACOGENOMIC EVALUATION OF ANTIHYPERTENSIVE RESPONSES (PEAR) STUDIES. *Clinical Pharmacology & Therapeutics* 2018; 103: S15. (PI-001). Abstract presented at the American Society for Clinical Pharmacology and Therapeutics 2018 Annual Meeting; March 22, 2018; Orlando, FL.
36. Shahin MH, Conrado DJ, Gonzalez D, **Gong Y**, Lobmeyer MT, Beitelshes AL, Boerwinkle E, Gums JG, Chapman A, Turner ST, Cooper-DeHoff RM, Johnson JA. β 2-ADRENERGIC RECEPTOR GENE AFFECTS THE NEGATIVE CHRONOTROPIC EFFECTS OF β -BLOCKERS IN THE PEAR AND PEAR2 STUDIES. *Clinical Pharmacology & Therapeutics* 2018; 103: S15. (PI-002). Abstract presented at the American Society for Clinical Pharmacology and Therapeutics 2018 Annual Meeting; March 22, 2018; Orlando, FL.

37. Magvanjav O, McDonough CW, **Gong Y**, Cooper-DeHoff RM, Hogan WR, Johnson JA. Combination antihypertensive therapy prescribing among outpatients: Evidence from an electronic health records database. *Clinical Pharmacology & Therapeutics* 2018, 103: S1 (PI-112). Abstract presented at the American Society for Clinical Pharmacology and Therapeutics 2018 Annual Meeting; March 22, 2018; Orlando, FL.
38. Magvanjav O, **Gong Y**, McDonough CW, Chapman AB, Turner ST, Gums JG, Bailey KR, Boerwinkle E, Beitelshes AL, Tanaka T, Kubo M, Pepine CJ, Cooper-DeHoff RM, Johnson JA. Towards precision therapy in hypertension: Genome-wide association study reveals genetic variants associated with uncontrolled blood pressure on thiazide diuretic/ β -blocker combination therapy in the Pharmacogenomic Evaluation of Antihypertensive Responses trial. PgmNr 2713/W. Presented at the 67th Annual Meeting of The American Society of Human Genetics, October 18th, 2017 in Orlando, Florida.
39. Mohamed Shahin, Akoluk A, Singh S, McDonough CW, **Gong Y**, Chapman AB, Turner ST, Gums JG, Beitelshes AL, Boerwinkle E, Cooper-DeHoff RM, Johnson JA. A Genome-Wide Association study identifies novel genetic signatures associated with Thiazide diuretics adverse metabolic events. PgmNr 2678/T. Presented at the 67th Annual Meeting of The American Society of Human Genetics, October 19th, 2017 in Orlando, Florida.
40. Singh S, **Gong Y**, McDonough CW, Bailey KR, Beitelshes AL, Boerwinkle E, Chapman AB, Gums JG, Turner ST, Cooper-DeHoff RM, Johnson JA. Genome-wide Association study reveals novel genetic markers associated with Chlorthalidone blood pressure response. PgmNr 2685/F. Presented at the 67th Annual Meeting of The American Society of Human Genetics, October 20th, 2017 in Orlando, Florida.
41. Yang G, Hamadeh IS, Katz J, Riva A, Langae TY, Moreb JS, **Gong Y**. *SIRT1* SNPs associated with bisphosphonate-related osteonecrosis of the jaw (ONJ). Poster presented at American Society of Bone and Mineral Research (ASBMR) # FR0003, Sep 8, 2017 in Denver, Colorado.
42. Arwood AM, McDonough CW, Cavallari LH, Elsey AR, Frye RF, **Gong Y**, Langae TY, Johnson JA, Weitzel KW. Equipping Health professional students to apply pharmacogenomic data to clinical decision making in real-world scenarios: comparison of an active engagement versus didactic teaching approach. Poster presented at Translational Science 2017 in Washington DC, April 19-21, 2017.
43. Chintan S, **Gong Y**, Szady A, Sun Qian, Pepine CJ, Langae T, Lucas AR, Moreb JS. Unanticipated cardiotoxicity due to targeted anticancer therapy in hematologic malignancies patients: Natural history and risk factors. *Cancer Research* 07/2017; 77(13 Supplement):987-987. Podium presentation at the American Association of Cancer Research (AACR) 2017 Annual Meeting in Washington DC, April 2, 2017.
44. Wokhlu A, **Gong Y**, Cooper-DeHoff RM, Smith SM, Handberg EM, Pepine CJ. Relationship between Diastolic Blood Pressure and All-Cause Mortality with Lower Systolic Blood Pressure among Hypertensive CAD patients: Long-term Follow-up of the US Cohort of the International VERAmapmil-SR Trandolapril Study (INVEST). *J Am Coll Cardiol.* 2017; 69 (11):1685. Poster presentation at the American College of Cardiology's 66th Annual Scientific Session in Washington DC on March 19, 2017.

45. **Gong Y**, Nguyen HK, Szady A, Hamadeh I, Lipori G, Sun Q, Cooper-DeHoff RM, Langaee TY, Shah C, Pepine CJ, Lucas AR, Moreb J. Cardiomyopathy Associated with Targeted Anticancer Therapies in Electronic Health Records. *J Am Coll Cardiol*. 2017; 69 (11):925. Poster presentation at the American College of Cardiology's 66th Annual Scientific Session in Washington DC on March 19, 2017.
46. Hamburg R, **Gong Y**, Moreb J, Pepine CJ, Lucas A, Szady A. Global longitudinal strain in patients with new left ventricular systolic dysfunction after anticancer targeted therapy. *J Am Coll Cardiol*. 2017; 69 (11):821. Poster presentation at the American College of Cardiology's 66th Annual Scientific Session in Washington DC on March 18, 2017.
47. El Rouby N, McDonough CW, **Gong Y**, McClure LA, Mitchell BD, Horenstein RB, Talbert RL, Bradford Y, Crawford DC, Ritchie MD, Gitzendanner MA, Takahashi A, Tanaka T, Kubo M, Pepine CJ, Benavente OR, DeHoff RM, Johnson JA. A GWAS of Resistant Hypertension in the INternational VERapamil SR-trandolapril Study (INVEST) and Secondary Prevention of Small Subcortical Strokes (SPS3). *Clinical Pharmacology & Therapeutics* 2017; 101:S27. (PI 029). Poster presentation at 2017 Annual Meeting, Washington Marriott Wardman Park, Washington, DC, March 15–18, 2017
48. Singh S, Alghamdi W, Arwood MJ, Bargal SA, de Oliveira F, Dumeny L, Wen-Yi L, Mehanna M, Stockard B, Yang G, Fredette N, Shahin M, Bailey KR, Beitelshes AL, Boerwinkle E, Chapman AB, Gums JG, Turner ST, **Gong Y**, McDonough CW, Cooper-DeHoff RM, Johnson JA. A Genome Wide Association Study to Identify Pharmacogenomic Variants Associated with Chlorthalidone Induced Glucose Change in African Americans. American Society for Clinical Pharmacology and Therapeutics. *Clinical Pharmacology & Therapeutics* 2017; 101:S9. (PT-019). This abstract was among the top-scored abstracts submitted this year to the ASCPT conference and was selected to receive ASCPT presidential trainee award.
49. Shahin MH, Michailidis G, **Gong Y**, Beitelshes AL, Chapman AB, Gums JG, Boerwinkle E, Turner ST, Cooper-DeHoff RM, Johnson JA. Thiazide-Induced Hyperuricemia: Novel Insights from Metabolomics and Genomics Integration in the Pharmacogenomic Evaluation of Antihypertensive Responses 2 (PEAR2) Study. *Clinical Pharmacology & Therapeutics* 2017; 101: S13. (PT-028). This abstract was among the top-scored abstracts submitted this year to the ASCPT conference and was selected to receive ASCPT presidential trainee award.
50. Costa Sa A, Webb A, **Gong Y**, McDonough CW, Shahin MH, Datta S, Langaee TY, Turner ST, Beitelshes AL, Chapman AB, Boerwinkle E, Gums JG, Scherer SE, Cooper-DeHoff RM, Sadee W, Johnson JA. Rna-Seq Analyses Identify Molecular Markers of Blood Pressure (BP) Response to Thiazide Diuretics (TD). *Clinical Pharmacology & Therapeutics* 2017; 101:S96 . (PWIV-001). Poster Walk presentation at the 2017 American Society of Clinical Pharmacology and Therapeutics Meeting, Washington, DC, March 15-18, 2017.
51. Cavallari LH, Denny JC, Lee CR, Beitelshes AL, Duarte JD, Kimmel SE, Voora D, McDonough CW, **Gong Y**, Wei WQ, Pratt VM, Chumnumwat S, Coons JC, Cooper-DeHoff

RM, Dave CV, Dillon C, Hamadeh IS, Hines L, Howell LA, Jeng LJ, Lee YM, Skaar TC, Sriramoju VB, Stevenson JM, Vesely MR, Wake D, Kreutz RP, Stouffer GA, Wilke RA, Empey PE, Limdi NA, Roden DM, Shuldiner AR, Johnson JA, Peterson JF. Prospective Clinical Implementation of CYP2C19-Genotype Guided Antiplatelet Therapy After PCI: a Multi-Site Investigation of MACE Outcomes in a Real-World Setting. *Circulation* 2016;134:e711-712 (abstract #21050). Presented as a Late-Breaking Clinical Science Special Report: Precision Medicine on the Front Lines at the American Heart Association's Scientific Sessions 2016. New Orleans, LA. November 15, 2016.

52. Lovato B, Weitzel W, Elsey A, McDonough C, **Gong Y**, Fillingim R, Schmidt S, Johnson J, Cavallari L. Factors influencing beliefs about pharmacogenetics testing in patients with chronic pain. *Pharmacotherapy* 2016;36(10):e144 (#455). Poster presentation at the ACCP Annual Meeting. October 23-26, 2016. Hollywood, FL.
53. Bargal S, Kight J, de Oliveira F, Shahin M, Langae T, **Gong Y**, Hamadeh I, Cooper-DeHoff R, Cavallari L. Implications of polymorphisms in BCKDK and GATA-4 genetic regions on stable warfarin dose in African Americans. *Pharmacotherapy* 2016;36(12):e267 (#250). Poster presentation at the ACCP Annual Meeting. October 23-26, 2016. Hollywood, FL.
54. Mehanna M, **Gong Y**, McDonough CW, Beitelshes A, Gums J, Chapman AB, Johnson J, Turner S, Cooper-DeHoff R. The role of plasma renin activity for improving precision of antihypertensive drug therapy in European Americans and African Americans. *Pharmacotherapy* 2016;36(12):e214 (#40). Poster presentation at the ACCP Annual Meeting. October 23-26, 2016. Hollywood, FL.
55. Elgendy I, Bavry A, **Gong Y**, Handberg E, Cooper-DeHoff RM, Pepine CJ. Long-term mortality in a cohort of hypertensive patients with Coronary Artery disease: results from an extended follow up of the International Verapamil/Trandolapril study (INVEST) Project. *J Am Coll Cardiol*. 2016; 67(13_S):2015-2015. Poster presentation at the American College of Cardiology in Chicago. April 4, 2016.
56. O. Magvanjav, C. W. McDonough, **Y. Gong**, L. A. McClure, R. L. Talbert, R. B. Horenstein, B. D. Mitchell, A. R. Shuldiner, O. R. Benavente, J. A. Johnson. Pharmacogenetic association of β 1-adrenergic receptor Ser49Gly polymorphism with outcomes in the Secondary Prevention of Small Subcortical Strokes (SPS3) trial. *Clinical Pharmacology & Therapeutics* 2016, 99: S19 (PT-17). March 12, 2016. San Diego, FL.
57. A. C. Sa, A. Webb, **Y. Gong**, C.W. McDonough, M.H. Shahin, T. Y. Langae, S.T. Turner, A. L. Beitelshes, A. B. Chapman, E. Boerwinkle, J.G. Gums, S. Scherer, R. M. Cooper-DeHoff, W. Sadee, J. A. Johnson. Hypertension (HTN)/Blood Pressure (BP) Signature Genes and BP Response to Thiazide Diuretics (TD): Results From Pear and Pear-2 Studies. *Clinical Pharmacology & Therapeutics* 2016, 99: S19 (PT23). Poster and Oral presentation at the American Society of Clinical Pharmacology and Therapeutics. March 10, 2016. San Diego, FL

58. M. H. Shahin, A.C. Sa, A. Webb, **Gong Y**, T. Langaee, C. W. McDonough, A. Riva, A. L. Beitelshes, A. B. Chapman, J. G. Gums, S. T. Turner, R. F. Frye, S. E. Scherer, W. Sadee, R. M. Cooper-DeHoff, J. A. Johnson. Finding a Needle in the Haystack for Thiazide Diuretic Response Using Genomics/Transcriptomics in the Pharmacogenomic Evaluation of Antihypertensive Responses (Pear) Study. *Clinical Pharmacology & Therapeutics* 2016, 99: S19. Poster presentation at the American Society of Clinical Pharmacology and Therapeutics. March 9, 2016. San Diego, FL
59. Mohamed H Shahin, Daniel M Rotroff, Amy Webb, **Gong Y**, Taimour Langaee, Caitrin W McDonough, Amber L Beitelshes, Timothy Garrett, John G Gums, Alison Motsinger-Reif, Arlene B Chapman, Stephen T Turner, Eric Boerwinkle, Reginald F Frye, Steven E Scherer, Wolfgang Sadee, Oliver Fiehn, Rhonda M Cooper-DeHoff, Rima Kaddurah-Daouk, and Julie A Johnson. *Circulation* 2015;132:A13621. Poster presentation at the American Heart Association 2015 Scientific Sessions. November 8, 2015. Orlando, FL.
60. de Oliveira FA, Shahin MH, **Gong Y**, McDonough CW, Beitelshes AL, Gums JG, Chapman AB, Boerwinkle E, Turner ST, Frye RF, Fiehn O, Kaddurah-Daouk R, Johnson JA, Cooper-DeHoff RM. Genomics-metabolomics Integrative Approach Reveals Novel Biomarkers in DPYS Associated With Higher Glucose Change After Treatment With Atenolol. *Circulation* 2015;132:A18338. Poster presentation at the American Heart Association 2015 Scientific Sessions. November 10, 2015. Orlando, FL.
61. N. El Rouby, C. W. McDonough, **Gong Y**, L. A. McClure, B. D. Mitchell, R. B. Horenstein, R. L. Talbert, A. Takahashi, T. Tanaka, M. Kubo, C. J. Pepine, R. M. Cooper-DeHoff, O. R. Benavente, A. R. Shuldiner, J. A. Johnson. Precision Medicine Approach to Resistant Hypertension: Genetic Markers of Resistant Hypertension Through a Genome-wide Association Study (GWAS) in the Secondary Prevention of Subcortical Strokes (SPS3). *Circulation* 2015;132:A15465. Poster presentation at the American Heart Association 2015 Scientific Sessions. November 9, 2015. Orlando, FL.
62. Cavallari LH, Magvanjav O, Anderson RD, **Gong Y**, Owusu-Obeng A, Kong B, Vo T, Ashton JN, Staley BJ, Eelsey AR, Allan RW, Starostik P, Cooper-DeHoff RM, Weitzel KW, Clare-Salzler MJ, Nelson DR, Johnson JA. Clinical implementation of *CYP2C19* genotype guided antiplatelet therapy reduces cardiovascular events after PCI. *Circulation* 2015;132:A11802. Poster presentation at the American Heart Association 2015 Scientific Sessions. November 9, 2015. Orlando, FL.
63. N. El Rouby, C. W. McDonough, **Y. Gong**, L. A. McClure, B. D. Mitchell, R. B. Horenstein, R. L. Talbert, A. Takahashi, T. Tanaka, M. Kubo, C. J. Pepine, R. M. Cooper-DeHoff, O. R. Benavente, A. R. Shuldiner, J. A. Johnson. Novel genetic loci for resistant hypertension discovered through a genome-wide association approach (GWAS) in the INternational VErapamil SR-Trandolapril STudy (INVEST) and the Secondary Prevention of Subcortical Strokes (SPS3) Study. Program/Abstract # 665. Presented at the 65th Annual Meeting of The American Society of Human Genetics, October 8th, 2015 in Baltimore, MD.
64. M. H. Shahin, A. C. Sa, A. Webb, **Y. Gong**, T. Langaee, C. W. McDonough, A. L. Beitelshes, A. B. Chapman, J. G. Gums, S. T. Turner, R. F. Frye, S. E. Scherer, W. Sadee, R. M. Cooper-DeHoff, J. A. Johnson. Identifying a Novel Hypertension Genetic

Signature Influencing the Blood Pressure Response to Hydrochlorothiazide Treated Patients. Program/Abstract #674. Presented at the 65th Annual Meeting of The American Society of Human Genetics, October 7th, 2015 in Baltimore, MD.

65. A. C. Sa, A. Webb, **Y. Gong**, C. W. McDonough, T. Y. Langaee, S. T. Turner, A. L. Beitelshes, A. B. Chapman, E. Boerwinkle, J. G. Gums, S. Scherer, R. M. Cooper-DeHoff, W. Sadee, J. A. Johnson. Molecular Markers of Blood Pressure Response to Thiazide Diuretics Identified Through Whole Transcriptome RNA-Seq Analysis, Program/Abstract #656. Presented at the 65th Annual Meeting of The American Society of Human Genetics, October 7th, 2015 in Baltimore, MD.
66. **Gong Y**, Katz J, Riva A, Davis N, Hamadeh IS, Bella Bernadett, Kosa J, Vaszilko M, Pelliccioni GA, Lakatos P, Moreb J, Langaee TY. Genetic variants associated with bisphosphonate-associated osteonecrosis of the jaw: A whole-Exome sequencing study. Poster presented at *American Society of Bone and Mineral Research (ASBMR) # S121*, Oct 10th, 2015 in Seattle, WA.
67. Solayman MH, Langaee T, **Gong Y**, El-Hamamsy M, El-Wakeel L, Boerwinkle E, Chapman A, Turner S, Gums J, Beitelshes A, Cooper-DeHoff R, Badary O, Johnson JA. Association of Plasma MicroRNA with Antihypertensive Response to Beta Blockers. *Clinical Pharmacology in Drug Development*. 2105; 4(S1) 58-59, DOI: 10.1002/cpdd.216.
68. M.H. Shahin, **Y. Gong**, T. Langaee, A.L. Beitelshes, D.M. Rotroff, A.B. Chapman, J.G. Gums, S.T. Turner, A. Motsinger-Reif, R.F. Frye, O. Fiehn, J.A. Johnson, R. Cooper-DeHoff, X. Han, R. Kaddurah-Daouk. Metabolomics, Genomics and Lipidomics Reveal Novel Signatures of Hydrochlorothiazide Response in Pharmacogenomic Evaluation of Antihypertensive Responses (Pear) Study. (2015), Poster Session I. *Clinical Pharmacology & Therapeutics*, 97: S21–S56. doi:10.1002/cpt.50.
69. M. H. Shahin, D. M. Rotroff, **Y. Gong**, T. Langaee, C. W. McDonough, A. L. Beitelshes, T. J. Garrett, A. B. Chapman, J. G. Gums, S. T. Turner, A. Motsinger-Reif, R. F. Frye, S. E. Scherer, W. Sadee, O. Fiehn, R. M. Cooper-DeHoff, R. Kaddurah-Daouk, J. A. Johnson. Integrating Metabolomics and Genomics Reveals Novel Biomarkers of Hydrochlorothiazide Response in Pharmacogenomic Evaluation Of Antihypertensive Responses (Pear) Study. (2015), Presidential Trainee Awards. *Clinical Pharmacology & Therapeutics*, 97: S11–S18. doi: 10.1002/cpt.48.
70. M. H. Shahin, D. M. Rotroff, **Y. Gong**, T. Langaee, C. W. McDonough, A. L. Beitelshes, T. J. Garrett, A. B. Chapman, J. G. Gums, S. T. Turner, A. Motsinger-Reif, R. F. Frye, S. E. Scherer, W. Sadee, O. Fiehn, R. M. Cooper-DeHoff, R. Kaddurah-Daouk, J. A. Johnson. Integrating Metabolomics and Genomics Reveals Novel Biomarkers of Hydrochlorothiazide Response in Pharmacogenomic Evaluation Of Antihypertensive Responses (Pear) Study. (2015), Oral Session III. *Clinical Pharmacology & Therapeutics*, 97: S103–S104. doi:10.1002/cpt.56.

71. S. Chang, **Y. Gong**, C.W. McDonough, N. Nasiri Kenari, T. Langaee, A.L. Beitelshes, J.G. Gums, A.B. Chapman, S.T. Turner, J.A. Johnson, R.M. Cooper-DeHoff. CORRELATING THE MELATONIN (MT) PATHWAY WITH ATENOLOL ASSOCIATED GLUCOSE DYSREGULATION IN THE PHARMACOGENOMIC EVALUATION OF ANTIHYPERTENSIVE RESPONSES (PEAR) STUDY. Presidential Trainee Awards. *Clin. Pharmacol. Ther.*, 2015 97: S17. doi:10.1002/cpt.48. Poster presentation at American Society for Clinical Pharmacology and Therapeutics Annual meeting on March 7, 2015. New Orleans, LA.
72. Smith MS, Huo T, **Gong Y**, Handberg EM, Gulati M, Merz NB, Pepine CJ, Cooper-DeHoff RM. Mortality and Cardiovascular risk associated with apparent treatment-resistant hypertension among women. *AHA 2014*
73. Kawaguchi-Suzuki M, Bril F, Cusi K, Langaee T, **Gong Y**, Frye RF. Role of Genetic Polymorphisms on the Improvement of Liver Histology after Pioglitazone Treatment in Patients with Nonalcoholic Fatty Liver Disease (NAFLD). *Hepatology* 2014;60(S1):591A. DOI: 10.1002/hep.27514.
74. El Roubly N, McDonough CW, **Gong Y**, Pepine CJ, Takahashi A, Tanaka T, Kubo M, Cooper-DeHoff RM, Johnson JA. Genome-wide Association Study of Resistant Hypertension in INVEST. Abstract/Program 702M. Poster presented at the 64th Annual Meeting of The American Society of Human Genetics, October 20, 2014 in San Diego, CA.
75. Sa ACC, Webb A, **Gong Y**, Langaee TY, Turner ST, Chapman AB, Gums JG, Scherer S, Cooper-DeHoff RM, Sadee W, Johnson JA. Identifying Differentially Expressed Genes Associated with Extreme Blood Pressure Response to Hydrochlorothiazide monotherapy. Abstract/Program 732M. Poster presented at the 64th Annual Meeting of The American Society of Human Genetics, October 20, 2014 in San Diego, CA.
76. Bavry AA, **Gong Y**, Handberg EM, Cooper-DeHoff RM, Pepine CJ. Aspirin use in hypertensive patients with stable coronary artery disease. *J American College of Cardiology* 2014. Poster presentation at ACC.
77. **Gong Y**, McDonough CW, Wang Z, Langaee TY, Beitelshes AL, Gums JG, Bailey KR, Boerwinkle E, Chapman AB, Turner ST, Cooper-DeHoff RM, Johnson JA. Genome-wide Association Analysis (GWAS) of Blood Pressure Response to Atenolol-Results from Pharmacogenomic Evaluation of Antihypertensive Responses Study. *Clin Pharmacol Ther* 2014; 95 (S1): S16. Oral presentation at American Society for Clinical Pharmacology and Therapeutics Annual meeting on March 20, 2014 Atlanta, GA.
78. McDonough CW, **Gong Y**, Langaee TY, Pepine CJ, Cooper-DeHoff RM, Johnson JA. A Pharmacogenomic Genome-wide Association Study for Adverse Cardiovascular Outcomes in the International Verapamil Trandolapril Study (INVEST). *Clin Pharmacol Ther* 2014; 95 (S1): S71. Poster presentation at American Society for Clinical Pharmacology and Therapeutics Annual meeting on March 21, 2014 Atlanta, GA.

79. Chang S, McDonough CW, **Gong Y**, Pepine CJ, Johnson JA, Cooper-DeHoff RM. A Pharmacogenomic Genome-wide Association Study (GWAS) for New onset diabetes in the International Verapamil SR-Trandolapril Study (INVEST). *Clin Pharmacol Ther* 2014; 95 (S1): S59. Oral presentation at American Society for Clinical Pharmacology and Therapeutics Annual meeting on March 20, 2014 Atlanta, GA.
80. Fontana V, McDonough CW, **Gong Y**, ElRouby NM, Sa AC, Pepine CJ, Cooper-DeHoff RM, Johnson JA. ATP2B1 Locus is associated with resistant Hypertension in the International Verapamil trandolapril Study-Genetic Substudy (INVEST-GENES). *Clin Pharmacol Ther* 2014; 95 (S1): S26. Poster presentation at American Society for Clinical Pharmacology and Therapeutics Annual meeting on March 20, 2014 Atlanta, GA.
81. Hamadeh IS, Langaee TY, **Gong Y**, Skaar TC, Johnson JA. Impact of CYP2D6 Polymorphisms on Clinical Response and Tolerability of Immediate Release Metoprolol. *Pharmacotherapy*. 2013 (10): E232-E232.
82. Erdine S, Pepine CJ, Mancia G, **Gong Y**, Butev F. Efficacy of Calcium Antagonist vs. Non-calcium Antagonist Strategy in Reduction of Heart Rate in Diabetic Hypertensive Patients with Coronary Artery Disease: Data from INVEST Study. *Journal of Hypertension*. 2013 (31): e194.
83. Erdine S, Pepine CJ, Mancia G, **Gong Y**, Butev F. The Efficacy of Calcium Antagonist vs. Non-calcium Antagonist Strategy in Reduction of Heart Rate in Hypertensive Patients with Coronary Artery Disease: Data from INVEST Study. *Journal of Hypertension*, 2013 (31): e333.
84. **Gong Y**, Moore MJ, Karnes JH, McDonough CW, Wang Z, Langaee TY, Beitelshes AL, Turner ST, Chapman AB, Gums JG, Bailey K, Boerwinkle E, Johnson JA, Cooper-DeHoff RM. Fasting Glucose Loci Associated with Glucose Response to Antihypertensives-Results from the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR). *Clin Pharmacol Ther* 2013; 93 (S1): S28. Poster presentation at American Society for Clinical Pharmacology and Therapeutics Annual meeting on March 7, 2013 Indianapolis, IN.
85. Cooper-DeHoff RM*, Hou W, Baillie R, Beitelshes AL, **Gong Y**, Chapman AB, Gums JG, Turner ST, Boyle SH, Zhu H, Wikoff WR, Fiehn O, Frye RF, Kaddurah-Daouk R, Johnson JA. Pharmacometabolomics reveals a novel signature for predicting beta blocker associated impaired fasting glucose. *Circulation*. 2012;126:A11088. Poster presentation at American Heart Association. Nov 20, 2012, Los Angeles, CA.
86. Winchester DE, **Gong Y**, Cooper-DeHoff RM, Handberg EM, Pepine CJ. Mortality associated with angina and blood pressure control among hypertensive patients with coronary artery disease: new data from extended follow-up of the International Verapamil SR-Trandolapril Study. *J American College of Cardiology* 2012; 59 (13): E1458. Poster presentation at ACC.

87. Bavry AA, **Gong Y**, Kumbhani DJ, Kowey P, Haththotuwa E, Handberg EM, Cooper-DeHoff RM, Pepine CJ. Predictors of Mortality among Patients with Hypertension and Coronary Artery Disease: the INternational VERapamil SR-Trandolapril STudy (INVEST). *J American College of Cardiology* 2012; 59 (13): E1496. Poster presentation at ACC.
88. Cooper-DeHoff RM, **Gong Y**, Handberg EM, Messerli F, Bakris G, Bavry AA, Pepine CJ. Treatment-Resistant Blood Pressure among Patients with Coronary Artery Disease-Cause for Concern: New data from the Extended Follow-up of the INternational VERapamil SR-Trandolapril STudy (INVEST). *J American College of Cardiology* 2012; 59 (13): E1498. Poster presentation at ACC.
89. **Gong Y**, McDonough CW, Wang Z, Cooper-DeHoff RM, Langae TY, Beitelshes AL, Turner ST, Chapman AB, Gums JG, Bailey KR, Boerwinkle E, Johnson JA. Hypertension susceptibility loci and blood pressure response to antihypertensives – results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. *Clin Pharmacol Ther* 2012; 91 (S1): S16. Poster presentation at American Society for Clinical Pharmacology and Therapeutics Annual meeting.
90. Moore MJ, **Gong Y**, Schmidt S, Hall K, Chapman AB, Langae TY, Gums JG, Cooper-DeHoff RM, Johnson JA. ANTIHYPERTENSIVE MEDICATION EXPOSURE AND ADVERSE GLYCEMIC EFFECTS: AN EVALUATION OF FASTING AND STIMULATED GLUCOSE, *Clin Pharmacol Ther* 2012; 91 (S1): S25. Podium presentation at American Society for Clinical Pharmacology and Therapeutics Annual meeting.
91. Moore MJ, **Gong Y**, Hou W, Chapman AB, Langae TY, Schwartz GL, Turner ST, Gums JG, Bailey K, Boerwinkle E, Beitelshes AL, Cooper-DeHoff RM, Johnson JA. CLINICAL PREDICTORS OF DYSGLYCEMIC EFFECTS ASSOCIATED WITH USE OF BETA BLOCKERS AND THIAZIDE DIURETICS. *Clin Pharmacol Ther* 2012; 91 (S1): S24. Podium presentation at American Society for Clinical Pharmacology and Therapeutics Annual meeting.
92. McDonough CW, Burkley B, **Gong Y**, Langae TY, Pepine CJ, Cooper-DeHoff RM, Johnson JA. Non-synonymous SNPs in *SELE*, *SELP*, and *SIGLEC12* associate with cardiovascular (CV) outcomes in the INternational VERapamil SR-Trandolapril STudy GENetic Substudy (INVEST-GENES). *Clin Pharmacol Ther* 2012; 91 (S1): S20. Poster presentation at American Society for Clinical Pharmacology and Therapeutics Annual meeting.
93. Karnes JH, McDonough CW, **Gong Y**, Langae TY, Pepine CJ, Johnson JA, Cooper-DeHoff RM. Alpha adducin-1 (*ADD1*) Single nucleotide polymorphism (SNP) Associated with new onset diabetes risk with Hydrochlorothiazide (HCTZ) therapy in the International verapamil sr trandolapril study (INVEST). *Clin Pharmacol Ther* 2012; 91 (S1): S21. Poster presentation at American Society for Clinical Pharmacology and Therapeutics Annual meeting.

94. Vandell AG, McDonough CW, Langaee TY, Burkley B, **Gong Y**, Turner ST, Gums JG, Chapman AB, Beitelshes AL, Cooper-DeHoff RM, Johnson JA. Association of *FTO* with Hydrochlorothiazide (HCTZ)-induced elevation in uric acid (UA) in African American (AA) hypertensives in the Pharmacogenomic Evaluation of Antihypertensive Response (PEAR) study. *Clin Pharmacol Ther* 2012; 91 (S1): S59. Poster presentation at American Society for Clinical Pharmacology and Therapeutics Annual meeting.
95. Karnes JH, Vo TT, **Gong Y**, Langaee TY, Beitelshes AL, Turner ST, Chapman AB, Gums JG, Bailey K, Boerwinkle E, Pepine CJ, Johnson JA, Cooper-DeHoff RM. *KCNJ1* SNPs are Associated with Increased Fasting Glucose and Risk of New Onset Diabetes during HCTZ Therapy. *Clin Pharmacol Ther* 2011; 89(S1):S46. Poster presentation at American Society for Clinical Pharmacology and Therapeutics Annual meeting.
96. Vandell AG, Lobmeyer MT, Gawronski B, Langaee TY, **Gong Y**, Beitelshes AL, Gums JG, Turner ST, Chapman AB, Cooper-DeHoff RM, Liggett SB, Johnson JA. Influence of G Protein Receptor Kinase 4 (GRK4) Polymorphisms on Blood Pressure Response to the Beta-blocker Atenolol. *Clin Pharmacol Ther* 2011; 89(S1):S74. Poster presentation at American Society for Clinical Pharmacology and Therapeutics Annual meeting.
97. Davis HM, **Gong Y**, Pepine CJ, Cooper-DeHoff RM, Johnson JA. Genetic Variation in the Calcium Signaling Pathway and Association with Outcomes in Hypertensive Coronary Artery Disease Patients. *Clin Pharmacol Ther* 2011; 89(S1):S20. Poster presentation at American Society for Clinical Pharmacology and Therapeutics Annual meeting.
98. **Gong Y**, Beitelshes AL, Lobmeyer MT, Langaee TY, Cooper-DeHoff RM, Wu J, Spertus JA, Province MA, Pepine CJ, Johnson JA. Chromosome 9p21 SNPs Haplotypes are Associated with Cardiovascular Outcomes in Patients with Coronary Artery Diseases. *Circulation* 2010;122:A16925. Oral presentation at American Heart Association Scientific session.
99. Bavry AA, Khaliq A, **Gong Y**, Handberg EM, Cooper-DeHoff RM, Pepine CJ. Effects of Chronic Nonsteroidal Anti-inflammatory Drugs among Patients with Hypertension and Coronary Artery Disease: Post Hoc Analysis from the INVEST Trial. *Circulation* 2010;122:A12424
100. Shroads AL, Langaee TY, Coats BS, Kurtz TL, Bullock J, Weithorn D, **Gong Y**, Wagner D, Ostrov DA, Johnson JA, Stacpoole PW. Human Polymorphisms in the Glutathione Transferase Zeta 1 Maleylacetoacetate Isomerase Gene Predict the Kinetics and Toxicity of Dichloroacetate. *Drug Metabolism Reviews*. 2010; 42: 204.
101. Karnes JH, George AM, **Gong Y**, Langaee TY, Stauffer LA, Burkley BM, Pepine CJ, Johnson JA, Cooper-DeHoff RM. New Onset Diabetes Risk Associated with Antihypertensive Therapy in Hypertensive Coronary Artery Disease Patients is Modified by a Single Nucleotide Polymorphism in the L-type Calcium Channel Alpha 1c Subunit (*CACNA1C*). *Clin Pharmacol Ther* 2010;87(S1):S45

102. Moore MJ, Chik VPW, **Gong Y**, Langaee TY, Chapman AB, Schwartz GL, Turner ST, Gums JG, Cooper-DeHoff RM, Beitelshes AL, Johnson JA. Association between Melatonin Receptor 1B Single Nucleotide Polymorphisms (SNPs) and Response to Antihypertensive Drugs. *Clin Pharmacol Ther* 2010;87(1):S45
103. Davis HM, Allen B, **Gong Y**, Cooper-DeHoff RM, Pepine CJ, Johnson JA. Clinical Association of Variation in the β 2 Regulatory Subunit of the Voltage-Gated Calcium Channel (CACNB2) with Outcomes in Hypertensive Coronary Artery Disease (CAD) Patients. *Clin Pharmacol Ther* 2010;87(1):S2
104. Davis HM, Allen B, **Gong Y**, Cooper-DeHoff RM, Pepine CJ, Johnson JA. Clinical Association of Variation in the β 2 Regulatory Subunit of the Voltage-Gated Calcium Channel (CACNB2) with Outcomes in Hypertensive Coronary Artery Disease (CAD) Patients. *Clin Pharmacol Ther* 2010;87(1):S66
105. Cooper-DeHoff RM, **Gong Y**, Marin J, Rosen A, Handberg EM, Johnson JA, Pepine CJ. Long-Term Mortality Associated With New Onset Diabetes in Hypertensive CAD Patients Following Exposure to Antihypertensive Medications: Findings from the INternational VERapamil SR-Trandolapril STudy (INVEST). *J American College of Cardiology* 2009;53:A224
106. Winchester DE, **Gong Y**, Handberg EM, Cooper-Dehoff RM, Pepine CJ. Incident or Continued Angina During Hypertension Treatment is Associated With Increased Risk of Death, MI, or Stroke Among Patients With Known CAD: A Substudy of The INternational VERapamil/Trandolapril STudy (INVEST). *Circulation* 2009;120:S440
107. Niu Y, Langaee TY, **Gong Y**, Moss JI, Cooper-Dehoff RM, Pepine CJ, Johnson JA. DNA Variations in Voltage-gated Calcium Channel Beta 2 Subunit (CACNB2) Gene, Functional Consequences, and Association with Adverse Cardiovascular Outcomes in the INternational VERapamil SR-trandolapril STudy-GENETic Substudy. *Circulation* 2008;118(18):S885
108. Hassan M, York KM, Li HH, Li Q, **Gong Y**, Langaee TY, Fillingim RB, Johnson JA, Sheps DS. B1-adrenergic Receptor Polymorphism Predicts Mental Stress-induced Myocardial Ischemia in Patients with Coronary Artery Disease. *J American College of Cardiology* 2008;51:A377
109. Navare HA, Beitelshes AL, **Gong Y**, Langaee TY, Cooper-Dehoff RM, Pepine CJ, Johnson JA. CACNA1C Polymorphisms and Cardiovascular Outcomes in the INternational VERpamil SR/Trandolapril STudy-Genetic Substudy (INVEST-GENES). *Clin Pharmacol Ther* 2008;83(S1):S4
110. Pacanowski MA, Cooper-DeHoff RM, **Gong Y**, Schork NJ, Pepine CJ, Johnson JA. Diabetes Risk Associated with β ₁-adrenergic Receptor Polymorphisms Differs by Antihypertensive Drug Therapy: Results from the INternational VERapamil SR/trandolapril STudy – GENETic Substudy (INVEST-GENES). *Clin Pharmacol Ther* 2008;83(S1):S83

111. Johnson AD, **Gong Y**, Wang D, Langaee TY, Shin J, Cooper-DeHoff RM, Schork NJ, Shriver MA, Binkley P, Pepine CJ, Johnson JA, Sadee W. Novel Promoter Polymorphisms in Angiotensin-I Converting enzyme (ACE) Associated with Clinical Outcomes in Hypertensive Coronary Artery Disease (CAD) Patients. *Clin Pharmacol Ther* 2008;83(S1):S8
112. Denardo SJ, Messerli FH, Aranda JM, Cooper-DeHoff RM, Handberg EM, Gong Y, Champion A, Pepine CJ. Association of 'J-shaped' Curves and Age: A Substudy of the International Verapamil SR-Trandolapril Study (INVEST). *Circulation* 2008; 118 (18): S1160
113. Shin J, Kline S, Moore M, **Gong Y**, Blianderi V, Schmalfuss CM, Schofield RS, Johnson JA. Diurnal Blood Pressure Pattern is Associated with Risk for Hospitalization or Death in Heart Failure. *Clin Pharmacol Ther* 2007;81:S15
114. Schentrup AM, Nino G, **Gong Y**, Lima JJ, Cooper-Dehoff RM, Pepine CJ, Johnson JA. LTA4H Variant Confers Drug Therapy-dependent Reduced Risk of Cardiovascular Events in INVEST (INternational VErapamil SR/Trandolapril STudy). *Clin Pharmacol Ther* 2007;81:S35
115. Pacanowski MA, **Gong Y**, Langaee TY, Cooper-DeHoff RM, Schork NJ, Pepine CJ, Johnson JA. Beta 2-adrenergic Receptor Polymorphisms and Antihypertensive Treatment Outcomes in the INternational VErapamil SR/Trandolapril STudy-GENetic Substudy (INVEST-GENES). *Clin Pharmacol Ther* 2007;81:S34
116. Langaee TY, Burkley B, **Gong Y**, Zineh I. Effects of CYP3A4 and CYP3A5 polymorphisms on cholesterol responses to atorvastatin. *Clin Pharmacol Ther* 2007;81:S89
117. Cooper-Dehoff RM, Gerhard T, **Gong Y**, Handberg EM, Messerli FH, Pepine CJ. Blood Pressure < 120/80 mm Hg is Risky in Elderly CAD Patients: Findings from the INternational VErapamil SR-Trandolapril STudy (INVEST). *Circulation* 2007;115:E258
118. Gerhard T, **Gong Y**, Beitelshees AL, Cooper-DeHoff RM and Johnson JA. Association between CV Outcomes, Diuretic use and the Alpha-adducin Gene: Results from the INternational VErapamil SR Trandolapril STudy (INVEST). *Pharmacoepidemiology and Drug Safety* 2006;15:S17-S18
119. **Gong Y**, Handberg EM, Gerhard T, Cooper-DeHoff RM, Johnson JA, Pepine CJ. Association of Systolic Blood Pressure (SBP) and Health Related Quality of Life in Patients with Coronary Artery Disease: An Analysis from the INternational VErapamil SR Trandolapril STudy (INVEST). *Circulation* 2006;114(8):576-577
120. Handberg E, **Gong Y**, DeHoff RC, Ried LD, Pepine CJ. Can An Assessment of Subjective Well Being Predict Outcomes in Patients with Hypertension and Coronary Artery Disease? A Report from the INternational VErapamil-SR/Trandolapril STudy (INVEST). *Journal of the American College of Cardiology* 2006;47(4):300A

121. Johnson JA, Karnes JH, Brunner M, **Gong Y**, Langaee TY, Cooper-DeHoff RM, Pepine CJ. Lack of Association of the Angiotension II Type I Receptor (AGTR1) 1166 A>C Polymorphism with Cardiovascular and Cerebrovascular Outcomes in Subgroup of Patients of the INternational VERapamil SR-Trandolapril STudy (INVEST). *Clin Pharmacol Ther* 2006;79(2):P43
122. Lobmeyer MT, Terra SG, **Gong Y**, Hamilton KK, Pauly DF, Patterson JH, Adams KF, Schofield RS, Hill JA, Aranda JM, Johnson JA. Synergistic Polymorphisms of β 1- and α 2C-Adrenergic Receptors and the Influence on Left Ventricular Ejection Fraction in Response to β -blocker Therapy in Heart Failure. *Clin Pharmacol Ther* 2006;79(2):P31
123. Shin J, Lobmeyer MT, **Gong Y**, Zineh I, Langaee TY, Yarandi HN, Pauly DF, Aranda JM, Schofield RS, Hill JA, Johnson JA. A Haplotype of β 2-adrenoceptor is Associated with the Increased Risk for Transplant or Death in Heart Failure Patients. *Clin Pharmacol Ther* 2006;79(2):P30
124. Brunner M, Karnes JH, **Gong Y**, Langaee TY, Cooper-DeHoff RM, Pepine CJ, Johnson JA. Association of Angiotension II Type I Receptor (AGTR1) 1166A>C Polymorphism with Blood Pressure Response to ACE inhibitor in a Subgroup of Patients of the INternational VERapamil SR-Trandolapril STudy (INVEST). *Clin Pharmacol Ther* 2006;79(2):P14
125. Beitelshees AL, **Gong Y**, Cooper-DeHoff RM, Burt L, Stauffer LA, Pepine CJ, Johnson JA. KCNMB1 Genotype Associated with Cardiovascular Outcomes in the INternational VERapamil SR-Trandolapril STudy (INVEST). *Clin Pharmacol Ther* 2006;79(2):P41
126. **Gong Y**, Beitelshees AL, Stauffer LA, Langaee TY, Cooper-DeHoff RM, Pepine CJ, Johnson JA. Beta Adrenergic Receptors Polymorphisms are Associated with Response to Beta-Blocker Therapy in the INternational VERapamil SR-Trandolapril STudy (INVEST). *Clin Pharmacol Ther* 2006;79(2):P30
127. Gerhard T, **Gong Y**, Beitelshees AL, Lobmeyer M, Schiefelbein L, Langaee TY, Cooper-DeHoff RM and Johnson JA. Association between CV Outcomes, Diuretic use and the Alpha-adducin gene: Results from the INternational VERapamil SR Trandolapril STudy (INVEST). *Circulation* 2005;112(17):U670
128. Zoo J, Vergara S, Chen S, Jiang J, Kaku M, Kohno S, **Gong Y**, Hurst I, Huang H, Holliday L. Characterization of the Actin-binding Activity of Subunit B of Vacuolar H⁺-ATPases *Journal of Bone and Mineral Research* 2005;20(9):S258-S258
129. Beitelshees AL, **Gong Y**, Cooper-DeHoff RM, Moss JI, Pepine CJ, Johnson JA. Variable blood pressure response to verapamil by KCNMB1 genotype. *Clin Pharmacol Ther* 2005;77(2):97
130. **Gong Y**, Beitelshees AL, Stauffer L, Gaston K, Sloan A, Yarandi HN, Langaee TY, Cooper-DeHoff RM, Pepine CJ, Johnson JA. Beta 2-adrenergic Receptor (B2AR)

Polymorphisms and Antihypertensive Response to Beta-blocker Therapy in the INVEST Trial. *Clin Pharmacol Ther* 2005;77(2):22

131. King MA, **Gong Y**, Meyers C, Hughes JA and Meyer EM. Localized Gene Transfer of K670N/M671L App into Rat Hippocampus Produces Mnemonic Deficits, Neuronal Degeneration, and Alpha7 Nicotinic Receptor Alterations. *Neurobiology of Aging* 2004;25:S225
132. Jiang J, Zuo J, **Gong Y**, Hurst IR, Holliday LS. Role of Phosphatidylinositol 3-Kinase (p110 alpha) in Osteoclasts. *Journal of Bone and Mineral Research* 2003;18:S237

INVITED PRESENTATIONS:

1. 03/19/2006. 'Beta Adrenergic Receptors Polymorphisms are Associated with Response to Beta-Blocker Therapy in the INternational VErampil SR-Trandolapril STudy (INVEST).' American Society for Clinical Pharmacology and Therapeutics Annual meeting.
2. 11/14/2006, Association of Systolic Blood Pressure (SBP) and Health Related Quality of Life in Patients with Coronary Artery Disease: An Analysis from the INternational VErampil SR Trandolapril STudy (INVEST). American Heart Association Scientific session.
3. 11/16/2010, 'Chromosome 9p21 SNPs Haplotypes are Associated with Cardiovascular Outcomes in Patients with Coronary Artery Diseases.' American Heart Association Scientific session, Chicago, IL.
4. 12/14/2011, 'GWAS, Expression and Pathway Analysis of Triglyceride Response to Simvastatin Therapy', Pharmacogenomics Research Network, PSTAR analysis workshop, Chicago, IL.
5. 10/12/2012, 'Application of Genetic Risk Scores in Antihypertensive Pharmacogenomics: Essential for Future Clinical Translation.' Pharmacogenomics Research Network Research in Progress Webinar, online
6. 03/20/2014, 'Genome-wide Association Analysis (GWAS) of Blood Pressure Response to Atenolol-Results from Pharmacogenomic Evaluation of Antihypertensive Responses Study'. American Society for Clinical Pharmacology and Therapeutics Annual meeting, Atlanta, GA.

Visiting Scholars Supervised:

Martin Brunner, MD. Medical University of Vienna, Austria. 2005-2006

Vanessa Fontana, PhD. State University of Campinas, Brazil. 2013

Ying Yuan, MD. Affiliated Cancer Hospital of Guangxi Medical University, China. 2016-2017

Postdoctoral Fellows Supervised:

Luba Keilbasa, PharmD. 2005-2006

Jaekyu Shin, PharmD. 2005-2007

Michael Pacanowski, PharmD. 2005-2008

Mohamed Shafiu, MD. 2008-2009

Maximilian Lobmeyer, PhD.	2009-2010
Hazem Elewa, PharmD, PhD.	2009-2010
Alexander Vandell, PharmD/PhD.	2010-2012
Caitrin McDonough, PhD.	2010-2013
Murali Munisamy, PhD.	2012-2013
Issam Hamadeh, PharmD.	2012-2016
Liming Weng, PhD.	2013-2015
Arda Akoluk	2016-2017
Mohamed Shahin	2016-2018
Sonal Singh	2015-2019
Marwa Tantawy	2019-present
Eric Pruitt	2019-present

Undergraduate students Supervised:

Zheng Li	2017-2017
----------	-----------

PharmD students Supervised:

Hoai Khanh Nguyen	2016-2017
Cherokie Boyd	2018-2019
Frances Pamittan	2019-2020

Graduate Committee

Committee Chair-PhD:

Guang Yang, 2016 to 2020. Dissertation title: 'Pharmacogenomics of drug induced osteonecrosis of the Jaw'. Current position: Postdoc Fellow, North Western University.

- Awards:
 - 2017 ASBMR Young Investigator Travel Award
 - 2018 PGRN ASHG Best Trainee Abstract Award
 - 2019 ASCPT Presidential Trainee Abstract Award
 - 2019 PGRN ASCPT Best Trainee Abstract Award
 - 2019 ASBMR Young Investigator Travel Award

Committee Member -PhD:

Maximilian Lobmeyer, BS. 2004 to May 2009. Dissertation title: "Genetic Variation of beta-adrenergic receptor kinase 1 and beta-arresting 1: Definition, functional consequences and clinical implications". Current position: Research Scientist, Boehringer Ingelheim.

Julio Duarte, Pharm.D, 2007 to August 2010. Dissertation title: "The Role of the AF9/Dot1a/Sirt1 Candidate Pathway on Patient Variability in Blood Pressure and Cardiometabolic Responses to Hydrochlorothiazide". Current position: Assistant Professor, Department of Pharmacotherapy and Translational Research, University of Florida.

Heather Davis, Pharm.D, 2008 to December 2011. Dissertation title: "Pharmacogenetic Assessment and Molecular Analysis of Calcium Signaling Pathway Variation". Current position: practicing pharmacist.

Jason Karnes, Pharm.D, 2009 to August 2012. Dissertation title: "Genetic, pharmacogenetic, and pharmacotherapeutic risk factors for thiazide-induced dysglycemia". Current position: Assistant Professor, University of Arizona College of Pharmacy.

Mariellen Moore, Pharm.D, 2008 to December 2012. Dissertation title: "Adverse Metabolic Effects of Antihypertensive Medications: Clinical, Genetic, and Molecular Predictors". Current position: practicing pharmacist.

Mohamed Hossam Shahin, 2011 to December 2015. Dissertation title: 'Pharmacogenomics, transcriptomics and metabolomics for the identification of novel predictors associated with blood pressure response'.

Shin-Wen Chang, 2011 to December 2015. Dissertation title: 'Identifying Pharmacogenomic Loci Associated with Antihypertensive Treatment related Glucose Dysregulation and Potential Underlying Mechanism Using Data from Three Clinical Studies'.

Marina Kawaguchi, 2012 to August 2015. Dissertation title: 'Drug disposition and response in nonalcoholic fatty liver disease'.

Ana Caroline Costa Sa, 2012 to August 2017. Dissertation title: 'Transcriptome Profiling in Hypertensive Patients with Extreme Blood Pressure Response to Thiazide Diuretics'.

Nihal El Roubi, 2013 to August 2017. Dissertation title: 'Identification of genetic determinants associated with resistant hypertension using genome-wide association analysis coupled with induced pluripotent stem cells (iPSC)'.

Oyunbileg Magvanjav, 2014 to April 2018. Dissertation title: 'Identifying predictors of difficult-to-treat hypertension through genomics, metabolomics and electronic health records data analyses'.

Bradley Stockard, 2014 to May 2019. Dissertation title: 'Global and Targeted Metabolomics in Pediatric AML Identify Metabolic Differences Associated with Patient Characteristics and Treatment Response.'

Yimei Huang, 2020 to present. Dissertation title: 'The Impact of Metabolic Syndrome on Heart Failure Including Pulmonary Hypertension as an Indicator.'

Franjo Ivankovic-Macgibbon, 2020 to present. Dissertation title: 'Statistical Genetics in Psychiatric Disorders'.

Member -MS:

Bin Zhang, MS, 2009
Felipe de Oliveira, MS, 2014-2016
Mai Mehanna, MS, 2015-2017
Wenyi Li, MS, 2016-2018

Patent:

UF#-14344 entitled "Pharmacogenetics for the Identification of Risk Factors for Development of Jaw Osteonecrosis in Patients on Biphosphonates" filed in September 2013

TEACHING

University of Florida

College of Pharmacy

Pharmacogenomics (PHA 6449)

2008-present. Course coordinator since 2013. Required graduate course. Delivered 6 lecture hours per semester on Pharmacogenomics to class size of 8~15.

Introduction to Quantitative Methods (PHA 5719)

2010-2015. Course Master. Required course for Second year Pharm.D students. Taught class sizes of 287 to 294. Delivered approximately 30 lecture hours per year on basics of biostatistics and literature evaluations as well as led 24 discussion sessions per year.

Interdisciplinary Family Health (BMS 6828/6829)

2008-2012. Facilitators for 12 first-year professional students per semester.

College of Medicine

Advances in Hypertension Research (GMS 6413)

2013-2016. Graduate course. Delivered 2 lecture hours per semester on Pharmacogenomics and hypertension to class size of 4~8.

SERVICE

PROFESSIONAL SERVICE

EDITORIAL BOARDS

Clinical Translational Science	2018 - present
PLOS ONE	2011 - 2016
Journal of Pharmacovigilance	2013 – 2016

MANUSCRIPT REFEREE:

American Journal of Cardiology
Clinical Cardiology
Clinical Pharmacology and Therapeutics

Clinical Epidemiology
Clinical Translational Science
Hypertension
Journal of the American College of Cardiology
Pharmacogenomics Journal
Pharmacogenomics
Pharmacotherapy
PLOS ONE
Medicine
The Annals of Pharmacotherapy Editorial Review
Gene and Nutrition
Circulation: Cardiovascular Genetics
Scientific Reports

PROFESSIONAL SOCIETIES AND ORGANIZATIONS

2001 - present	Member, American Association of Pharmaceutical Scientists (AAPS)
2004 - present	Member, American Society of Clinical Pharmacology and Therapeutics (ASCPT)
2005 - present	Member, American Heart Association (AHA)
2006 - present	Member, International Society of Genetic Epidemiology (ISGE)
2014 - present	Member, American Society of Human Genetics (ASHG)
2015 - present	Member, American Society of Bone and Mineral Research (ASBMR)
2016 - present	Member, American College of Cardiology (ACC)

UNIVERSITY SERVICE

College of Pharmacy

- Curriculum Assessment Committee, 2010-present
- Faculty Search Committee, 2011-present
- Faculty advisor, 2011-present
- Admission Committee, 2014-2016
- Financial Aids/Scholarship Committee, 2016-present